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Abstract
The role of Human Immunodeficiency Virus type 2 (HTV-2) viral load has been studied in 
West Africa in order to understand how this infection differs from HTV-1 and why the 
majority of HIV-2 infected individuals live for long.
Using a polymerase chain reaction (PCR) based-assay, it was found that the level of HTV-2 
provirus was surprisingly high in HTV-2 seropositive people who live long without sign of 
immunosuppression; in contrast the rate of HTV-2 replication reflected by RNA viral load 
was found low. However, HIV-2 replicates to a high titre in some HTV-2-infected people 
whose disease progresses rapidly to death. Longitudinal follow-up demonstrated that base­
line HTV-2 RNA viral load predicts the rate of CD4^ T cell decline and death but the level 
of proviruses is a less sensitive predictor.
Cytotoxic T-lymphocyte activity (CTL) against HTV-2 structural proteins, especially Gag, 
was found in most HTV-2 infected people and was inversely correlated with HTV-2 proviral 
load. Strong CTL activity was consistently found in people who did not have progressive 
disease, suggesting that CTL play an important role in controlling HTV-2 replication.
Co-infection with human T-lymphotropic virus type I (HTLV-I) occurred frequently in 
HTV-2-infected people in a village in Guinea-Bissau but did not seem to enhance HTV-2 
viral load. However an increase in HTV-2 viral load was found in an HTV-2-infected 
individual with malaria parasitaemia, suggesting that malaria infection enhances HTV-2 
viral load.
The majority of people who are dually seroreactive for both HTV-1 and HTV-2 arc infected 
with both viruses but some subjects are dually seroreactive because antibodies against one
vi
type cross-react with the other type of HIV. These cross-reactive antibodies may be 
distinguished by antibody dilution analysis. Other dually seroreactive people harbour an 
undetectable level of HTV-2 provirus and HTV-2 proviral load tended to be low in advanced 
disease while HTV-1 proviral load was high.
vu
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Chapter 1.
General Introduction.
Acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency virus 
(HIV). The epidemic of this virus in Central and East Africa started in the late 1970’s and 
early 1980’s (Clumeck et al., 1984; Piot et al., 1984; Van de Perre et al., 1984; Brun- 
Vezinet et al., 1984; Serwadda et al., 1985; Kreiss et al., 1986; Quinn et al., 1986). It was 
well established before the virus was discovered and related to the disease (Barre-Sinoussi 
et al., 1983; Popovic et al., 1984). A new United Nations report in 1997 has estimated that 
20,800,000 people are living with HTV in subSahara Afiica which amounts to about two 
thirds of the 30.6 imlhon people living with the virus in the world. The HTV virus, which 
has spread in pandemic form in Afiica and in other parts of the world, and has caused AIDS 
in the vast majority of infected people is HTV type 1 (HIV-1). On the other hand there is 
second type of HTV (HTV-2) which occurs on a smaller scale and is of considerably less 
virulence. Therefore it is believed that an understanding of real differences between the two 
types of HIV is important since this information may provide a deeper understanding of the 
nature and pathogenesis of both infections. Thus this thesis focuses on HTV-2 infection.
l.a. General review of HTV-2 research 
l.a .1. History of HIV-2 discovery
HTV-2 was first isolated and described in 1986 in two West Afiican patients with the AIDS 
who were repeatedly negative for serum antibodies to HTV-1 (Clavel et al., 1986). Soon 
after more cases of ATDS with the new type of HIV were reported; clinical features were 
similar to those in patients with HIV-1 and all patients were from West Afiica (Brun- 
Vezinet et al., 1987, Clavel et al. 1987).
l.a .2. HIV-2 Epidemiology
i. Geographic distribution
Subsequent epidemiological surveys have revealed that HTV-2 is mainly confined to West 
Afiica (reviewed by De Cock et al. 1989, 1991a, 1993). HTV-2 infections were also 
reported outside West Afiica in countries or areas which have a present or past Portuguese 
connection: Angola (Bottiger et al., 1988), Mozambique (Barreto et al., 1993), Portugal 
(Smallman-Raynor and Cliff, 1991), Brazil (Cortes etal, 1989), Southern India (Pfutzner et 
al, 1992). Although sporadic cases of HIV-2 infection have been reported throughout 
Europe and in the north America, most infections have been in persons fi-om or previously 
resident in West Afiica (Smallman-Raynor and Cliff, 1991, O’Brien et al., 1992).
ii. HIV-2 epidemic in The Gambia and surrounding countries
In surrounding countries such as Senegal, Guinea-Bissau, HTV-2 does not appear to be a 
new infectious agent since the incidence of HTV-2 did not increase during the study period 
(Kanki et al., 1994; Poulsen et al., 1997). In The Gambia, numbers of newly diagnosed 
HTV-positive patients attending the MRC hospital are shown in Figure 1.1 and indicate that 
the number of newly diagnosed HTV-2-positive patients remained the same whereas the 
number of newly diagnosed HTV-1-positive patients has increased fi-om around 1990. Two 
cross-sectional community-based studies were conducted in 1988 (Wilkins et al. 1992) and 
1993/5 (O’Donovan et al. 1996) and three cross-sectional surveys of commercial sex 
workers (CSW) were done in 1988 (Pepin et al. 1991a), 1989 (Pepin et al., 1991b) and 
1992/3 (Hawkes et al., 1994). The data are summarised in Table l.a.l and also show that 
the seroprevalence of HTV-2 was constant while the seroprevalence of HTV-1 has begun to 
increase.
----- A — ■ mv-i
B HIV-2
B Dual
I
1
I I I I i  I
Year
Figure 1.1. Number of HIV seropositive patients who were 
newly diagnosed at the MRC hospital.
(Ariyoshi et al., 1998) .
Number HIV-1® fflV-2® Dual '
Community-based survey
1988* 4,228 <0.1% 1.1% -
1993/5t 29,670 0.55% 1.15% 0.05%
CSW survey*
1988 355 1.7% . 25.7% \'.l%
1989 241 ’ 4.6% 28.6% 2.5%
1992/3 213 13.6% 26.7% 5.6%
Table 1.1. The prevalence of HIV-1, HIV-2 and dual seroreactivity in The Gambia.
* The seroprevalence in the cluster survey was extracted from the paper(Wilkins et al. 
1992); tPregnant women attending antenatal clinic at the eight major government health 
centres (O’Donovan et al. 1996); ^Commercial sex workers in 1988 (Pepin et al. 1991a), 
1989 (Pepin et al., 1991b), 1992 (Hawkes et al., 1994);® % ofHIV-l/HIV-2 dually 
positive individuals were added.
iii. Age-specific prevalence o f HIV-2
HIV-2-mfected individuals are older than HTV-1-infected individuals. A survey of pregnant 
women has shown that the mean age of HIV-2 seropositive pregnant women in The Gambia 
was 27.8 years old which was significantly older than that of HIV-1 seropositive pregnant 
women, being 23.6 years old (p<0.01) (D O’Donovan et al., 1996). The difference is clearer 
in the comparison of surveys in two rural communities: the peak ages of HTV-2 prevalence 
in a rural community in Guinea-Bissau were 45-54 years old for men and 35-44 years old 
for women (Wilkins et al., 1993) whereas the peak age of HTV-1 prevalence in a rural 
community in Uganda was 25-34 years old for both men and women (Mulder et al., 1994). 
This difference may be because HTV-2-infected individuals live longer than HIV-1-infected 
individuals and/or because the risk of HTV-2 infection is higher in the older individuals 
(Aaby et al., 1996; Poulsen et al., 1997).
iv. Transmission o f HIV-2
Risk factors for HTV-2 infection were studied in West Afiica and found to be similar to 
those for HTV-1 infection, suggesting that the main route of HTV-2 transmission is 
heterosexual (reviewed by De Cock et al. 1991a). Mother-to-child transmission of HTV-2 
also occurs (Morgan et al., 1990; Adjorldo-Johnson et al., 1994; Whittle et al., 1997). 
Nevertheless the rate of transmission is significantly lower in HTV-2 infection than in HTV-1 
infection in both heterosexual (Kanki, et al. 1994) and mother-to-child routes: the rate of 
perinatal transmission in HTV-1 was reported to be about 15% to 35% (reviewed by 
Newell, 1993) whereas that in HTV-2 was found to be 0% to 4% (Poulsen et al., 1992; 
Adjorldo-Johnson et al., 1994; Whittle et al., 1997).
l.a .3. Clinical features and natural history of HIV-2 infection
It was initially believed that the clinical picture of HTV-2-induced ADDS was similar to that
of HIV-l-induced AIDS (Clavel et al., 1987; Bnm-Vezinet et al., 1987). Autopsy results 
from Abidjan have also shown the pathologies of patients who died with HIV-2 were similar 
to those with HTV-1 except for three conditions, all more frequent in HTV-2 deaths: i) 
severe multi-organ cytomegalovirus infection, ii) HTV encephalitis, iii) cholangitis. (Lucas et 
al., 1993). More recently it has been noticed that among patients attending the MRC 
Hospital, HTV-1-infected patients were 12.4 times more likely to have Kaposi’s sarcoma 
than HTV-2-infected patients even after adjusting for CD4^ cell count and age (Ariyoshi et 
al., 1998). However cervical cancer precursor lesions were reported to be similarly 
associated with both HTV-1 and HTV-2 (Langley et al., 1996). More detail clinical analysis 
of HTV-2-induced AIDS as compared with HTV-1-induced AIDS is necessary.
Although HTV-2 was first noticed in symptomatic patients who were diagnosed as AIDS 
(Clavel et al., 1986, 1987; Brun-Vezinet et al., 1987), it has been widely believed that HIV- 
2 is less pathogenic than HTV-1. Cross-sectional studies showed that the mean CD4^ cell 
count among HTV-2-infected individuals was significantly lower than HTV-uninfected 
controls but higher than that in HIV-1-infected individuals (Lisse et al., 1990; Pepin et al., 
1991b; Kestens et al., 1992). Also survival analysis of HTV-2 infected individuals at the 
MRC hospital indicated that HTV-2-infected patients live longer than HTV-1-infected 
patients (Whittle et al., 1994). The most striking evidence for the better clinical course of 
HTV-2 infection has derived from cohorts of community-based populations or 
seroconverters. Two community-based surveys in Guinea-Bissau have shown that the 
mortality rate ratio between HTV-2-infected and HTV-uninfected individuals was very low, 
from two to four fold depending upon the length of follow-up (Poulsen et al. 1989, 1997; 
Ricard et al. 1994). Intriguingly the longer the subjects were followed up the lower the 
mortality rate ratio (Poulsen et al., 1997). This was in contrast to a similar study in HTV-1 
infection in a rural area of Uganda where the mortality rate ratio was 20 among the age
group corresponding to the HTV-2-cohort (Mulder et al., 1994; Poulsen et al., 1997), 
though a formal comparison between the mortality rate among HTV-l-infected individuals 
and HTV-2-infected individuals in the same geographical area has not been made. A cohort 
of a limited number of HIV-1 and HIV-2 seroconverters among CSWs in Senegal has been 
described. This cohort demonstrated that the time taken to develop AIDS or an abnormal 
CD4^ cell count was longer in HTV-2 than HTV-l-seroconverters; the study showed that . 
33% of 31 HTV-1-seroconverters developed AIDS within 5 years whereas none of 32 HTV- 
2-seroconvertors developed AIDS within this period (Marlink et al., 1994). The absence of 
HTV-2 fast progressors in their cohort may be due to the small number of subjects or to the 
short period of follow-up. A report from Europe has described a HTV-2 seroconverter who 
had a rapid decline in CD4^ cell count and progressed to ATDS within 36 months (van der 
Ende et al., 1996). Fast-progressors with HTV-2 infection are also described in Chapter 4. 
Therefore there is a dichotomy in HTV-2 disease progression; certain individuals when 
infected with a particular strain of HTV-2, have as poor clinical prognosis as that of HTV-1. 
An understanding of why some HTV-2-infected individuals progress fast is equally 
important in order to answer the question why the prognosis of HIV-2 is, in general, better 
than HTV-1.
l.a .4. HIV-2 Virology
In this section, virological and molecular biological studies of HTV-2 are reviewed.
i. Structure o f HIV-2
The morphological structure of HTV-2 as observed by electron-microscopy is similar to 
HTV-1 (Clavel et al. 1986). The organisation of the HTV-2 genome, identifying the 
structural, regulatory and accessory genes and their major gene products, is shown in Figure
1.2. The genomic structure of HTV-2 is also similar to HIV-1 (Guyader et al. 1987) except 
that the vpu gene is present only in TUV-l/STVcpz whereas the vpx gene is present only in 
HTV-2/STV (Cohen et al., 1988; Henderson et al., 1988).
ii. Significance o f the vpx and the vpu genes
The vpx gene may have originated from the vpr gene as vpr and vpx share considerable 
sequence similarity (Tristem et al., 1990, 1992). In STV model, both vpr and vpx are 
required for pathogenesis (Gibbs et al., 1995). However the role of vpx gene in relation to 
the non-pathogenic properties of HTV-2 has not been clarified. It is also important to study 
functions of the vpu gène as it may contribute to the increased virulence of HTV-1 relative 
to HIV-2. Recently the Vpu protein has been reported to have three biological functions: 
augmentation of virus particle release, degradation of newly synthesised CD4, and down 
regulation of the surface expression of MHC class I molecule (Kerkau et al., 1997).
iii. Genotypic and phylogenetic analysis o f HIV-2
Sequences of HTV-2 viral proteins are only distantly related to that of HTV-1. Amino-acid 
sequence homology between HTV-2 and HTV-1 varies from ~ 40% in Env to ~ 60% in Pol 
and Gag (Guyader et al. 1987). HTV-2 is much closer to STVmac or STVm as the amino-acid 
homology is 70-75% in Env and -85% in Pol and Gag (Chakrabarti et al. 1987; Hirsch et 
al. 1989).
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A high degree of sequence diversity has also been noticed in HIV-2 viruses and it has been 
postulated that multiple independent introductions of genetically diverse SIVm viruses into 
human population occurred (Sharp et al., 1994). So far fiye subtypes (A-E) have been 
described but only subtype A and B which are associated with clinical disease, have been 
successfully isolated (reviewed by Sharp et al. 1994). There have been only single 
representatives of subtype C,D and E. The sequence of subtype D is so close to SIYm or 
SIVnuc viruses that the virus could not be separated into distinct phylogenetic lineages from 
viruses of primate origin (Gao et al. 1992). Geographical distribution of HIV-2 subtype has 
not been extensively studied yet. Limited studies have shown that sequences of HIV-2 gag 
gene in 67 HrV-2-infected individuals living in a rural village, Guinea-Bissau were all 
subtype A (Xiang et al, 1996). Non-A subtype has not been reported as a dominant subtype 
in any country.
Recombination of HTV-l subtypes takes place (Robertson et al., 1995; Myers et al., 1995). 
Recombination of HIV-2 subtypes has also been reported. HIV- 2 7 3  i2a which originated
I
from mV-2 patient from Abidjan, Côte d’Ivoire, has a mosaic genome of HIV-2 subtype A 
and subtype B (Gao et al. 1992).
Information on intra-patient variability of HIV-2 has been limited but one small study with 5 
HIV-2 infected patients suggested that the average intra-patient nucleotide variability rate 
was lower among healthy patients than among patients with ADDS (Sankale et al., 1995).
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TV. Regulation o f HIV~2 gene expression
a. Structure o f HIV-2 LTR is different from that o f HIV-1 LTR
The HTV long terminal repeat (LTR) contains cw-acting viral elements which play a crucial 
role in the regulation of HIV RNA synthesis and is divided into three functional distinct 
regions designated U3, R, and U5. Nucleotide sequence homology between HTV-l and 
HIV-2 LTRs is low, 30-40% (Guyader et al., 1987). The U3 domain of both HIV-1 and 
HIV-2 LTRs contains basal promoter elements, including a TATAA box and SPl binding 
sites. Additional cw-acting sequences in the U3 domain differ considerably between HIV-1 
and HIV-2. The HIV-1 LTR has two kB regulatory elements whereas the HIV-2 LTR does 
not have a tandem repeat of the kB  regulatory element in the region but contains other 
elements: PuBl, PuB2 and Pets which are not found in HIV-1 (Markovitz et al., 1990, 
1992; Tong-Starksen et al., 1990) (Figure 1.3). Mutation experiments suggested that 
activation of the HIV-2 enhancer is dependent on at least the four cw-acting elements 
(Markovitz et al., 1992). Later, a novel cw-acting element has been identified immediately 
upstream of the kB site, designated peri-xB, in the HIV-2 LTR but not in the HIV-1 LTR 
(The peri-xB site is not shown in Figure 1.3). The factor(s) binding to the peri-xB site has 
not been identified but appears to be monocyte-specific (Clark et al., 1995).
11
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b. Conditions which activate the enhancer are different between HIV-1 and HIV-2 
Not surprisingly the HTV-l and HIV-2 enhancers are induced differently. For example, a 
cytokine, tumour necrosis factor alpha (TNF-a) induces HTV-l transcription primarily 
through the two kB elements in the HTV-l enhancer by inducing a DNA binding protein, 
NFkB (reviewed by Matsuyama et al., 1991). On the other hand, HIV-2 transcription is 
only weakly induced by TNF-a perhaps because NF-kB does not strongly activate the 
single kB element in the HIV-2 enhancer (Hannibal et al., 1993). Another example is that 
the triggering of the CD3 component of the T-cell receptor complex with anti-CD3 
antibodies stimulates HTV-2 transcription but not HTV-l (Markovitz et al., 1990). This 
stimulation of HTV-2 with anti-CD3 antibodies was thought to be mediated by a different 
cellular factor, AP3, binding to an upstream enhancer which is not present in the HIV-1 
LTR (Tong-Starksen et al., 1990; Markovitz et al., 1992). Further understanding of the 
difference in transcriptional enhancers of HTV-l and HTV-2 in wild-type HTV is warranted.
c. HIV-2 regulatory genes and their response elements in RNA
Regulation of HTV gene expression is also controlled by two viral regulatory proteins: Tat 
and Rev. Both Tat and Rev are nuclear proteins that bind to the viral RNA at specific sites 
called the Tat-responsive element (TAR) and the Rev-responsive element (RRE), 
respectively. Tat augments level of viral RNA at the transcriptional level whereas Rev acts 
at the post-transcriptional level and is essential for the expression of the viral structural 
proteins such as the gag/pol and env mRNA (reviewed by Felber & Pavlakis, 1993).
The structure of HTV-2 Tat is similar to that of HTV-l Tat (Elangovan et al., 1992). 
However the secondary structure of HTV-2 TAR differs considerably from that of HTV-l 
TAR as HTV-2 TAR can be folded into a complex structure with three stem-loops whereas 
HTV-l TAR can be folded into a simple one-stem structure (Fenrick et al., 1989; Berkhout
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1992). Interestingly HIV-2 Tat rrwz^-activates the HIV-1 LTR less efiBciently than HIV-1 
Tat while both HTV-2 Tat and HTV-l Tat efficiently f>-aw-activate the HTV-2 LTR 
(Emerman et al., 1987). The amino-acid differences in the basic domains but not the core 
domains of the Tat proteins appear to be responsible for this incomplete reciprocity 
(Elangovan et al., 1992).
HTV-2 Rev and HTV-l Rev are also functionally and structurally similar. However while 
HTV-l Rev can efficiently complement an HIV-2 provirus lacking a functional HTV-2 Rev 
protein, HTV-2 Rev can not effectively substitute for HTV-l Rev (Lewis et al., 1990; Malim 
et al., 1989; Sakai et al., 1991).
d  Significance o f nef gene.
The importance of Nef in the AIDS pathogenesis has been demonstrated in the rhesus 
monkey model where functional nef expression is required for both high viral load and 
disease progression (Kestler et al., 1991). The importance of Nef was also suggested in 
HTV infection of humans as a «e/-defective HTV-l has been found in several long-term non- 
progressors (Deacon et al., 1995; Kirchhoff et al., 1995). Therefore it is crucial to 
understand the biological function of the nef gene. Several in vitro experiments have shown 
that the HTV-l Nef protein has several biological activities: down regulation of cell surface 
expression of CD4 (Garcia et al., 1991; Aiken et al., 1994), augmentation of infectivity of 
HIV-1 particle (Chowers, et al., 1994; Miller et al., 1994; Spina et al., 1994), activation of 
infected cells (Du et al., 1995), down regulation of MHC class I molecule (Schwartz et al.,
1996), and up-regulation of Fas Ligand expression (Xu et al., 1997). The last two activities 
may be responsible for the virus evading cytotoxic T-cell response. The function of down 
regulation of CD4 expression was thought to render cells resistant to viral superinfection 
(Benson et al., 1993). On the other hand very little study has been done on the function of
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HTV-2 Nef obtained from the early stage of infection. Deletion of we/-defective wild-type 
HTV-2 has not been reported yet.
V. In vitro biological characteristics o f HIV-2
Biological properties of HTV-2 are similar to HTV-l. The first prototype of HTV-2, HTV- 
2r o d  obtained from a West Afiican with AIDS, grows rapidly to a high titre in vitro and 
shows cytopathic effects on cultured cells similar to that of HTV-l such as syncytia- 
formation and cell lysis (Clavel et al. 1986). Less cytopathic HIV-2 strains, HIV-2uli from a 
patient with neurologic symptoms and HTV-2st from an asymptomatic individual, have been 
reported. I hey do not form syncytia, nor do they kill CD4-bearing cells or down-regulate 
cell surface CD4 (Evans et al., 1988; Kong et al., 1988). As has been well-described in 
HTV-l (Asjo et al., 1986; Cheng-Mayer et al., 1988; Tersmette et al., 1988), diversity of 
biological properties exists among HTV-2 isolates and these correlate with clinical status. 
Isolates with high replicative ability which replicate in tumour cell lines and induce syncytia 
were obtained from symptomatic patients with a low CD4^ cell count whereas less 
replicative isolates which lack the ability to replicate in tumour cell lines or to induce 
syncytia were obtained from asymptomatic individuals and from some symptomatic patients 
(Albert et al., 1990a; Schulz et al., 1990). Simon et al., reported that the rate of isolation 
was significantly lower in HIV-2 than HTV-l among patients with a relatively high CD4^ 
cell count (Simon et al., 1993). This finding may also reflect on the lower replication- 
capacity of HIV-2. However in this study the in vitro replication-capacity of HTV isolates 
was not studied. More recently biological properties of HTV-2 have been related to 
genotype of V3 loop; the V3 loop amino acid sequence was more heterogenous and had 
higher net charge in viruses with rapid/high replication capacity (Albert et al., 1996). A 
comparison of biological properties between HTV-l and HTV-2 in isolates from community- 
based subjects yet to be made.
15
V/. Cell tropism o f HIV-2
Like HIV-1, HTV-2 also uses the CD4 molecule as the primary cell attachment receptor 
(Dalgleish et al., 1984; Sattentau et al., 1988) and HIV-2 can infect a similar range of CD4 
expressing human T-cell and macrophage cell lines as that of HTV-l (Evans et al., 1988; 
Franchini et al., 1989; Albert et al., 1990a; Schulz et al., 1990). However some HTV-2 
strains can also infect certain CD4‘ human cell lines and this infection is enhanced by soluble 
CD4 (Clapham et al., 1992).
Recent discoveries of chemokine receptors which act as second receptors for HIV-1 entry 
have provided more insights into mechanisms of the diversity of cell tropism (Feng et al., 
1996; Deng et al., 1996; Dragic et al., 1996; Alkhatib et al., 1996). Limited information on 
chemokine receptor usage among HIV-2 viruses have suggested that HTV-2 laboratory 
established strains and primary isolates use the same chemokine receptors as HTV-l. CCR5 
or CCR3 were used by HTV-2 isolates from asymptomatic individuals whereas CXCR4 was 
used by HTV-2 T-tropic strains and isolates from AIDS patients (Sol et al., 1997). However 
the pattern of co-receptor usage seems to be more complex and wider for HTV-2 than HTV- 
1 since an HTV-2 envelope protein has been shown to use a wider repertoire of chemokine 
receptors including CCRl, CCR2, CCR4, and CXCR2, to induce fusion in a cell-to-cell 
fusion assay (Bron et al., 1997) and also primary isolates of fast-growing HTV-2 have been 
shown to use multiple chemokine receptors: CCRl, CCR2b, CCR3, CCR5 and CXCR4 
(Heredia et al., 1997; McKnight et al., manuscript submitted). The differences in the usage 
of chemokine co-receptor may be important for determining the difference in the pattern of 
disease. Further studies of co-receptor usage for primary isolates with slow/low growing 
capacity from HTV-2 long-term non-progressors are needed.
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l.a.5. Host-immune response to HIV-2
z. Humoral immunity
Neutralising antibodies (NA) against HTV-l viruses have been extensively investigated since 
early stage of HTV-l research (Weiss et al., 1985, 1986; Robert-GurofiF et al., 1985) and 
neutralisation targets on HTV-l Env have been well-characterised: these are linear epitopes 
in the third (V3) and the second (V2) hyper-variable domains (Matsushita et al., 1988; 
Javaherian et al., 1989; Broliden et al., 1990; Fung et al., 1992; McKeating et al., 1993) of 
external glypoprotein, gpl20, and also in transmembrane glycoprotein, gp41 (Muster et al., 
1993). Non-linear, conformationally sensitive epitopes as well have been described in the 
CD4 binding region of gpl20 (Lasky et al., 1987; Steimer et al., 1991, Kaiig et al., 1991; 
Thali et al., 1991). Fewer studies of NA in HTV-2 infection have been done. Like HTV-l, it 
has been suggested that there were neutralisation targets on the exposed domains of IHV-2 
Env: in the V2 and the V3 loop and one conformational epitope outside VI, V2, and V3 
(Bjorling et al., 1994; Traincard et al., 1994; McKnight et al., 1996), though more studies 
are needed as previous reports have shown contradictory results (Norrby et al., 1991; Babas 
et al., 1994; Matsushita et al., 1995). Emergence of NA escape viruses in HTV-l-infected 
individuals has been observed by several groups (Albert et al., 1990b; Homsy et al., 1990; 
Tremblay & Wainberg 1990; Montefiori et al., 1991). However study of anti-HTV-2 NA in 
clinical samples has been limited; one study showed that NA against autologous virus 
isolates have been readily demonstrated in 9 HTV-2-infected individuals (Bjorling et al., 
1993), though the autologous NA titre was not related to the rate of HTV-2 disease 
progression. NA escape virus has not been described in HTV-2-infected individuals. NA in 
sera from HTV-2-infected individuals have been shown to cross-neutralise STV (Robert- 
Guroff et al., 1992) and also HTV-l laboratory strains (Weiss et al., 1988; Bottiger et al.,
1990). Nevertheless, cross-neutralising against HTV-l primary isolates have not been 
studied.
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A few studies have shown the existence of antibody-dependent cellular cytotoxicity 
(ADCC) in sera from HTV-2-infected individuals (Bjorling et al., 1991; Von Gegerfelt et al.,
1993) but the importance of ADCC remains largely unknown.
ii. Cell-mediated immunity
Cytotoxic T-cells (CTL) are thought to play an important role in eradicating virus in infected 
cells during acute infection and in controlling viral replication in persistent infection (reviewed by 
McMichael & Walker, 1994). Extensive studies of HIV-1-specific CTL have shown that in most 
HTV-l-infected asymptomatic individuals CTL can be demonstrated against the structural 
proteins Gag, Pol and Env (Walker et al., 1988; Nixon et al., 1988; Lamhamedi-Cherradi et al.,
1992), that the precursor frequency of HIV-l-specific CTL is unusually high in such individuals 
(Hofrenbach et al., 1989; Gotch et al., 1990; Carmichael et al., 1993), and that high levels of 
CTL are associated with the slow rate of disease progression (Rinaldo et al., 1995a; Riviere et 
al., 1995; Klein et al., 1995). Albeit HIV-1 persists in most infected individuals, as the virus can 
acquire mutations to escape the CTL immune response and the emergence of such CTL escape 
mutants appears to associate with progression to AIDS (Phillips et a., 1991; Goulder et al.,
1997). It has also been shown that the rapid reduction of primary plasma viraemia coincided with 
the development of HTV-l-specific CTL (Koup et al., 1994; Borrow et al., 1994) but not the 
neutralising antibodies against autologous viruses (Aiiyoshi et al., 1992; Connick et al., 1996). 
More recently a rapid selection of CTL escape viruses during primary infection has been 
demonstrated (Borrow et al., 1997) and the induction of memory CTL, particularly those against 
Env, during early infection has been related with slower rate of disease progression (Musey et 
al., 1997).
Studies of CTL activities in HTV-2 infection have been limited. CTL activities in HTV-2-
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infected individuals were first studied by Gotch who showed that HTV-2 Gag CTIi were 
demonstrable in fresh PBMC in 5/7 (70%) of HTV-2-infected individuals and identified a 
B53 restricted CTL epitope in HTV-2 Gag (Gotch et al., 1993). CTL activities in HTV-2- 
infected individuals have also been studied in Chapter 5 of this thesis where it has been 
demonstrated that HIV-2-specific CTL, predominantly targeting Gag, were detected in all 
HTV-2-infected asymptomatic individuals. This CTL activity was inversely correlated with 
HTV-2 proyiral load (Ariyoshi et al., 1995; Chapter 5). Later, additional CTL epitopes, 
restricted by HLA B35 and B5801, were found in HTV-2 Gag, Pol and Nef. Of those 
epitopes, amino acid sequence in a Nef epitope, restricted by B35 was completely 
conserved between HTV-l and HIV-2. Interestingly although there are some differences in 
amino acid sequences between HTV-2 Gag or Pol CTL epitopes restricted by B35 or B5801 
and the corresponding regions in HTV-l Gag or Pol, the corresponding HTV-l peptides 
were cross-reactively recognised by HTV-2 CTL (Rowland-Jones et al., 1995; Bertoletti, et 
al., 1998). CTL escape mutant from HTV-2-specific CTL has not been described yet.
l.b. Review of serodiagnosis of UlV-infections in West Africa
The serodiagnosis of HIV-infection is complex in West Africa because of the presence of 
both HTV-l and HTV-2. Especially the significance of dual seroreactivity, which is 
frequently observed in the region, remains unclear as both HTV-l and HTV-2 proviruses 
were detected only in about half of dually seroreactive individuals (George et al., 1992; 
Peeters et al., 1994). This issue is further discussed in Chapter 7. Accurate serological 
diagnosis of single HTV-l or HTV-2 infections and of HTV-l/HTV-2 dual infection is 
essential for seroepidemiological studies, for the understanding of the pathogenic properties 
of the two viruses, and for the study of interaction between the two types of HTV.
Because of significant amino acid sequence homology between HTV-l and HTV-2, cross-
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reactive antibodies are common. The WHO recommended criterion for HTV-2 positivity on 
Western blot depends on the antibody recognition of envelope bands (World Health 
Organisation 1990). However even the Env protein which is known to be less homologous 
than Gag or Pol protein, is often recognised by heterotypic sera in the Westerti-Blot assay; 
cross-reactivity seems to be more extensive for HTV-2 sera against HTV-l antigens than the 
reverse (Tedder et al, 1988; De Cock et al, 1991a). To increase the specificity of HTV 
antibody assays, synthetic peptides corresponding to the immunodominant region of 
 ^transmembrane glycoprotein gp36/gp41 of HTV-l and HTV-2 where the antibody responses 
are type-specific, have been used (Norrby et al., 1987; Gnann et al. 1987; Baillou et al,
1991). These peptide-based methods were found to be more specific than Westem-Blot (Dc 
Cock et al, 1990, 1991b). Type-specific competitive ELISA assays using recombinant Env 
protein were also shown to be highly specific (Tedder et al., 1988) and by titrating antibody 
with the competitive ELISA assays, it is possible to distinguish true dual seroreactivity from 
cross-reactivity (Berry et al, 1993). The latter technique has been further pursued in a large 
number of subjects in Chapter 7.
I.e. The role of HIV-1 viral load in HIV-1 pathogenesis
I.c.1. HIV-1 pathogenesis.
Although it has been convincingly shown that HTV infection leads to ADDS (Darby et al.,
1995), the real mechanisms of immunosuppression caused by HTV-l have not been clearly 
understood. A number of hypotheses have been raised (reviewed by Weiss, 1993; Pantaleo, 
1993b). These are a) direct killing of HTV-infected cells by HTV-mediated cytopathic 
effects, b) killing of HTV-infected cells by HTV-specific immune responses, c) killing of 
HTV-uninfected bystander cells by cell-to-cell fusion, d) autoimmune destruction triggered 
by the virus through molecular mimicry of cellular antigens, e) apoptosis induced by HTV 
viral gene products for instance HTV-l Tat, Env (Westendrop et al., 1995; Li et al., 1995),
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e) dysfunction of antigen-presenting cell inducing an imbalance in the Tnl-type and Th2 
type responses (Meyaard et al., 1993; Clerici & Shearer, 1993). This thesis focuses on the 
role of HTV viral load in the pathogenesis, which does not necessarily exclude other 
mechanisms of pathogenesis. The role of HTV viral load is discussed in detail below. The 
Possible role of CTL in the immuno-pathogenesis is also discussed in Chapter 5 in the 
context of HIV-2 infection.
1.C.2 HIV-1 virus population dynamics in vivo
The virus has two phases in its life cycle: RNA virus as a virion existing outside cells and 
provirus which is DNA copy of viral RNA existing inside cells. Thus both RNA and DNA 
viral load need to be measured. However in the early days of the studies of HIV-1 viral 
load, only the technique to quantify DNA viral load was available and the importance of the 
virus in lowering CD4^ cell count was controversial, because during the asymptomatic 
phase the level of HTV-l-infected CD4^ cells was thought to be too low to cause 
progressive CD4^ cell loss (Sheppard et al., 1993). Since the advent of very potent anti­
retroviral drugs and of accurate assays to quantify HTV-l RNA virus in plasma, two groups 
have successfully demonstrated that by carefully measuring the decay of HTV-l virus in 
plasma in patients receiving potent anti-retroviral drug that not only the virus but also 
productively infected cells turn-over very rapidly with a short half life of few days (Wei et 
al., 1995; Ho et al., 1995). This insight into the dynamics of the HTV-l virus and virus- 
infected cells has at least partly answered the question as to why patients lose CD4"^  cells 
despite a low frequency of HTV-infected cells. Later more detailed studies on HTV-l RNA 
viral kinetics and HTV-l provirus have been published (Perelson et al., 1996, 1997; Chun et 
al., 1997). The current view of HTV-l population dynamics in vivo is summarised in a 
schematic diagram (Figure 1.4). In five HTV-l-infected patients with mean plasma virions of 
216,000 (range, 12,000, 643,000) copies per ml, the half life of HTV-l RNA in plasma was
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found to be very short, approximately 6 hours and on average 10x10® virions were 
estimated to be produced every day (Perelson et al., 1996). Thus a substantial number of 
cells must be actively producing HTV-l viruses to maintain this level of viral RNA in 
plasma. The observed exponential decline of HTV-l RNA in plasma in the patients on anti­
retroviral drug therapy implies that the half life of such productively infected cells is also 
very short, about 1.6 days (Perelson et al., 1996), though there is small proportion (<1%) of 
cells which are long-lived despite being productively infected; the half life of these cells 
being 1-4 weeks (Perelson et al., 1997). Therefore as the diagram shows, the major 
contributor to cell death by HIV is the productive infection of cells where the number of 
productively infected cells is reflected by the level of viral RNA in plasma.
The majority of productively infected cells are thought to result from de novo infection of 
CD4^ cells. Whether a newly infected cell becomes latently infected or productively 
infected, appears to depend upon the state of activation of the cell: if the cell is activated 
when infected with HIV-1, productive infection results whereas if the cell is resting, the 
infection becomes latent (Stevenson et al., 1990). Therefore the size of the population of 
activated cells susceptible to HTV-l infection determines the number of productively 
infected cells. Chun et al., showed that the vast majority of HIV-1 proviruses are in either 
unintegrated form or integrated form but replication-incompetent, though there are some, 
resting T-cells which are latently infected with replication-competent HTV-l proviruses 
which has integrated. However the total load of such cells is estimated to be low (<10^ 
cells) (Chun et al., 1997). Thus although these latently infected resting T-cells can be 
reactivated to produce the virus, the number of viruses produced by such cells appears to be 
small (Wei et al., 1995; Ho et al., 1995).
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Figure 1.4. Schematic diagram of HIV-1 population dynamics in vivo.
The figure shoWs estimated half life (ti/2 ) (Perelson et al., 1996 & 1997) and 
estimated numbers of virions produced per day (Perelson et al., 1996) and cells 
(Chun et al., 1997).
l.c.3. Measurement of HlV-1 viral load
i. Viral load in peripheral blood versus lymphoid tissue
Because of its accessibility most investigators have used peripheral blood to measure viral 
load on the assumption that the level of virus in plasma and in peripheral blood mononuclear 
cells reflects the total amount of RNA virus or provirus in the body. However the major site 
for viral replication appears to be in lymphoid tissue (Armstrong & Home 1984; Pantaleo et 
al., 1991, 1993a; Embretson et al., 1993). A study of HTV-l and HTV-2 infection in The 
Gambia has recently shown that although the fi-equency of infected cells was, on average, 
higher in lymph-node than in peripheral blood, the values at the two sites were closely 
correlated (Jobe et al., manuscript in preparation). Moreover there is vigorous lymphocyte 
circulation between lymphoid tissue and peripheral blood, the mean transit time of a 
lymphocyte in peripheral blood being only 30 minutes, and roughly 500x10® lymphocytes 
travel through the blood each day, which is about the same as the number of lymphocytes 
within the whole body (Westermann & Pabst 1990). Thus measurement of viral load in 
PBMC is likely to be representative of the total population of lymphocytes in the body.
HTV-l virions produced in lymphoid tissue are assumed to diffuse into lymphoid fluid and 
eventually enter into the venous blood. Some HTV virions are trapped by follicular dendritic 
cells in lymph-nodes (Armstrong & Home 1984; Pantaleo et al., 1993a; Embretson et al.,
1993). However the quantity of HTV-virions trapped by these cells in the lymph-node has 
not been accurately estimated but appears to be negligible as compared with total number of 
virions produced into plasma. Two reports have suggested that there is a positive 
correlation between plasma viraemia and proviral DNA load in the lymphoid tissue (Sei et 
al., 1994; Dianzanietal., 1996).
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ii. Methods used to measure viral load
Different techniques have been applied to evaluate viral load. The early HTV-l viral load 
studies were done using limiting dilution tissue-culture techniques to determine tissue- 
culture-infective doses (Ho et al., 1989; Coombs et al., 1989) so was a HTV-2 viral load 
study (Simon et al., 1993). The tissue-culture method has the advantage that it can quantify 
replication competent viruses but the method is tedious and also is not sensitive especially 
when detecting viruses in plasma of patients with a high CD4^ cell count (Coombs et al., 
1989; Venet et al., 1991; Saag et al., 1991; Dewar et al., 1992; Simon et al., 1993; Ariyoshi 
et al., 1994). Moreover results are often difficult to interpret because of variation in the 
susceptibility of donor cells (Wainberg et al., 1987, Cloyd & Moore, 1990; Paxton et al.,
1996) and in HTV-2 infection, the detection of the virus in the culture may be often limited 
by the slow/low replication property of HTV-2.
PCR techniques were applied first to quantify viral load using the limiting dilution technique 
(Schnittman et al., 1989; Simmonds et al., 1990; Zhang et al., 1991; Hsia & Spector, 1991) 
and later without this step. Most techniques use external controls to estimate number of 
viral DNA copies (Genesca et al., 1990; Lee et al., 1991; Yerly et al., 1992; Ferre et al., 
1992; Escaich et al., 1992; Bieniasz et al., 1993; Chevret et al., 1994) or viral RNA copies 
(Holodniy et al., 1991; Aoki-Sei et al., 1992, Semple et al., 1993). The number of HTV viral 
RNA was not sufficiently high to be detected by direct extraction of RNA using the 
guanidinium thiocyanate-phenol-chloroform extraction method or polyethylene glycol 
method (Holodniy et al., 1991; Semple et al., 1991). Early investigators therefore used 
ultra-centrifugation (Zhang et al., 1991; Ottmann et al., 1991; Aoki-Sei et al., 1992; Piatak 
et al., 1993) or immuno-precipitation (Semple et al., 1993) to concentrate the virions in 
plasma in order to improve the sensitivity. In this thesis and also in other studies a technique 
described by Boom et al., was used in which viral RNA was precipitated by silica particles
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(Boom et al., 1990; van Gemen et al., 1993, 1994; Beny et al., submitted). This RNA 
extraction technique is also incorporated into a commercial assay, NASBA. Another 
technique to measure viral RNA in plasma is branched-DNA which relies on signal 
amplification rather than the PCR amplification. Nevertheless the technique is less sensitive 
than PCR-based methods and it is difficult to develop as home-made assays.
The use of external controls may result in falsely low measurements due to the presence of 
non-specific inhibitors of PCR in blood samples, such as residual heparin or haem 
containing proteins, causing tube-to-tube variation of efficiency of PCR amplification. To 
over-come this problem, competitive PCR techniques have been developed, in which 
internal controls have been spiked into the clinical samples (Scadden et al., 1992; Piatak et 
al., 1993; van Gemen et al., 1993). However, the use of adequate RNA purification 
methods, such as the method of Boom, usually overcomes problems of non-specific 
inhibitors and allows the use of external controls which are less time consuming.
Recently several commercial assays have become available to quantify HTV-l RNA viral 
load: these are a PCR-based assay with internal controls (Amplicor, Roch), an RNA 
amplification method with internal controls (NASBA, Organon), and a branched DNA assay 
with external controls (BDNA, Chiron). However as most HTV-l subtypes in The Gambia 
are not subtype B viruses (Ariyoshi, et al., 1996), the sensitivity of those commercial assays 
for detecting non-type B viruses may not be as high as that for type B viruses (Loussert- 
Ajaka, et al., 1995; Clewley et al., 1995). Moreover no commercial or non-commercial 
molecular based assay for measuring HTV-2 DNA or RNA has been available until recently 
(Berry et al., 1994, manuscript submitted).
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l.c.4. HTV-l viral load as a marker of disease progression
Although all early studies have shown that HTV-l proviral load is inversely correlated with 
patient’s CD4^ count or with their disease status (Ho et al., 1989; Coombs et al., 1989; 
Simmonds et al., 1990; Holodniy et al., 1990; Lee et al., 1991; Aoki-Sei et al., 1992; Yerly 
et al., 1992; Ferre et al., 1992; Bieniasz et al., 1993; Chevret et al., 1994), these cross- 
sectional observations did not indicate whether the increased viral load was the cause or the 
result of immunosuppression. Very few studies have shown that high proviral DNA load 
predicts the rate of disease progression (Schnittman et al., 1990). However the expression 
of HTV-l mRNA in PBMC was shown to predict future HTV disease progression (Saksela 
et al., 1995). Furthermore since techniques to measure viial RNA load in plasma have 
become widely available and been applied to cohort studies, evidence has accumulated that 
RNA viral load is a strong prognostic marker of HTV-l disease progression. Studies of 
HTV-l seroconverters have shown the pattern of RNA viraemia after initial infection is 
predictive of clinical outcome (Mellors et al., 1995; Henrard et al., 1995; de Wolf et al.,
1997) and a community-based cohort of homosexual men has shown that plasma viral load 
at entry to the study was a better predictor of progression to AIDS and death than was the 
CD4^ cell count (Mellors et al., 1996).
l.c.5. HTV-l long-term non-progressors
Although disease in HTV-l-infected individuals progresses faster than in HTV-2-infected 
individuals, a subgroup (approximately 5%) of HTV-l-infected individuals remain clinically 
healthy and immunologically normal for more than a decade and these individuals are 
termed long-term non-progressors (reviewed by Schrager et al., 1994). Several 
immunological and virological studies have been carried out to characterise long-term non- 
progressors (Cao et al., 1995; Pantaleo et al., 1995; Rinaldo et al., 1995a; Montefiori et al., 
1996; Ferbas et al., 1995; Pilgrim et al., 1996). Most of these studies have consistently
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shown low levels of viral load in long-term non-progressors and a combination of strong 
virus-specific immunity including cytotoxic T-lymphocyte activities and neutralising- 
antibody response. The better clinical outcome of some long-term non-progressors has 
been thought to be due to a viral genetic factor, a defective we/gene (Deacon et al., 1995; 
Kirchhoff et al., 1995) but the defect in the nef gene does not seem to be common in other ' 
long-term non-progressors (Huang et al., 1995; Michael et al., 1995).
More recently several groups have demonstrated that a host genetic factor, a 32 bp deletion 
in the CCR5 gene is associated with slow progression especially in early stage of infection 
(Dean et al, 1996; Michael et al., 1997a; Meyer et al., 1997; Stewart et al., 1997). Although 
another host genetic factor, a substitution of the valine at position 64 to isoleucine in the 
CCR2 gene has also been suggested to confer some protection against disease progression 
(Smith et al., 1997), the finding has not been repeated by other group (Michael et al., 
1997b). Chemoldnes, MIP-la, MIP-ip, and RANTES have been shown to inhibit HTV-l 
and HTV-2 infection through blocking the interaction with the viral co-receptors (Cocchi et 
al., 1995). However neither serum levels of MTP-la, MIP-ip and RANTES nor the . 
production of these chemoldnes by in vitro stimulated cultured cells seems to correlate with 
disease progression (McKenzie et al., 1996; Clerici et al., 1996).
l.d. The aim of this thesis:
The AIDS unit at MRC Laboratories, The Gambia has addressed the general question, 
“Why do HTV-2-infected individuals live longer than HTV-l-infected individuals?” Answers 
to this question may enhance understanding of HIV-pathogenesis in general and also may 
provide a clue to prolong the life of HTV-l-infected individuals. As HTV-l viral load plays 
an important role in HTV-l pathogenesis, it is postulated that HTV-2 viral load also plays a
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crucial role in HIV-2 pathogenesis. However studies of HTV-2 viral load have been very 
limited (Simmons et al., 1993, Berry et al., 1994). Thus the studies of HTV-2 viral load and 
the clarification of the in vivo HTV-2 replication in HTV-2-infected individuds at different 
clinical stages may provide important answers to the general question. For this reason, the 
role of HTV-2 viral load in HTV-2 pathogenesis has been the focus of this thesis which has 
been set up with the following aims:
1) To correlate HTV-2 viral load with the disease progression as determined by mortality or 
loss of CD4^ cells.
2) To correlate HTV-2 viral load with HTV-2-specific cytotoxic T-lymphocyte activities.
3) To study the impact of co-infections such as HTLV-I and malaria on HTV-2 viral load.
4) To study the interaction between HTV-l and HTV-2.
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Chapter 2. 
Materials and Methods. 
2.a. Patients and materials
2.a.l. A community-based study in a rural village in Guinea-Bissau
The study village, Caio is located in the north-west of Guinea-Bissau where approximately 
5000 adult people are living in a thick palm-tree forest (Figure 2.1). The mam economic 
activities of the area are rice growing, palm oil and palm wine production. It is known that 
many men leave to work elsewhere in Guinea-Bissau, or in neighbouring countries in West 
Africa or in Europe. It is also known that many women leave to work and a significant 
proportion of those are involved in prostitution in the region’s urban centres. Between 
August 1989 and May 1991, the first serosurvey was conducted (Wilkins et al. 1993). A 
total of 2770 subjects aged >15 years were tested and 220 subjects with HIV-2 infection 
were identified. Between March and June 1991, 132 HIV-2 seropositive subjects and 160 
age and sex matched HIV seronegative controls were examined by a study clinician, and 
10 ml of heparinised blood (preservative free heparin 10 lU/ml) was collected for 
CD4/CD8 subset analysis and for plasma and peripheral mononuclear cells (PBMC)
(Ricard et al. 1994). Plasma samples were snap-frozen in liquid nitrogen and PBMC 
samples were cryopreserved with 10% dimethyl sulphoxide (DMSO) using liquid nitrogen 
vapour phase at the field laboratory. The population in the study village has been followed 
with annual censuses. These samples collected in 1991 were used in Chapter 3 apd Chapter 
6.a. In 1996, 86 HIV-2 seropositive subjects and 117 HTV seronegative controls who were 
recruited for the 1991 case-control study, were clinically and immunologically re­
examined and their plasma and PBMC samples were stored as described above. In order to 
study the effect of malaria infection during the rainy season, 33 HTV seropositive and 22 
HIV seronegative subjects were bled both in May and in October 1997. These samples 
were analysed in Chapter 6.b.
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Figure 2.1, Map of West Africa.
The study village, Caio is indicated.
2.a.2. A hospital-based study at the MRC hospital in The Gambia
In The Gambia, which has a population of approximately one million, there are three major 
hospitals of which two, the Royal Victoria Hospital and the MRC hospital are located in 
the Western division where approximately half of the population lives (Figure 2.2). These 
hospitals serve as the referral centres for the entire country, and are open to all patients at 
minimal cost. HIV-testing is offered free of charge to patients with clinical symptoms 
suggestive of AIDS. Patients with TB, individuals with a high risk of infection such as 
commercial sex workers (CSWs), STD patients or spouses of HTV positive partners and all 
blood donors are also tested free of charge. Since May 1086 all patients who were 
diagnosed as HIV-seropositive at the two hospitals have been enrolled in a hospital-based 
cohort study. In addition, HIV seropositive CSWs who were identified by three cross- 
sectional serosurveys in 1988, 1989 and 1992, have also been enrolled. Patients were asked ' 
to attend at the MRC hospital to see the study clinicians every three months. Every six 
months, 15-20ml of heparinised blood was taken. PBMC were separated on Ficoll hypaque 
(Lymphoprep, Nycomed Pharma AS. Oslo, Norway), and then cryopreserved in liquid 
nitrogen; 1-3ml EDTA treated blood was taken to determine CD4/CD8 subset by FACScan 
(Beckton-Dickinson, Belgium) analysis. Study subjects in Chapter 4, 5, and 7 were 
recruited from this study.
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2.a.3. A community-based perinatal transmission study in The Gambia
Between January 1993 and March 1995, 29,670 women attending the eight major 
government antenatal clinics were screened by serology for HIV (O’Donovan et al. 1996). 
This survey identified 110 HIV-1, 250 HIV-2 and 10 dually seropositive pregnant women. 
All women who were dually seroreactive were also enrolled in Chapter 7.
Verbal informed consent was obtained from all patients who were pre- and post-test 
counselled. All studies in this thesis were approved by The Gambia Govemment/MRC 
Ethical Committee.
2.b. Serological diagnosis.
2.b.l. Serological diagnosis of HIV infection.
HTV serostatus was initially screened by a combined competitive enzyme-linked 
immunosorbent assay (ELISA) (Combined Wellcozyme, Murex, U.K.). This screening 
assay is based on highly purified antigens of the core and envelope recombinant proteins of 
HIV-1 isolate (Sattentau et al., 1986). As the cross-reaction at the core protein alone is not 
satisfactory to detect all HIV-2 sera (Denis et al., 1988), an immunodominant epitope of 
the HTV-2 transmembrane envelope (Norrby et al., 1987), which was prepared by peptide 
sythesis techniques, was added to ensure sensitivity. If the sample was positive by the 
screening test, the type of HTV was determined by a type specific competitive ÉLIS A 
(Wellcozyme I and Wellcozyme II, Murex, U.K.). The HTV-l-type specific ELISA is 
based on a fusion protein of p24-transmembrane envelope protein from HIV-1 isolate 
(Sattentau et al., 1986) and HTV-2-type specific competitive ELISA is based on 
transmembrane envelope protein from HTV-2 virus (Berry et al., 1993). If the sample was 
greater than the cut-off which was 3 standard deviations higher than the mean of the 
negative values for competitive ELISA, it was regarded as positive. If a sample was
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positive for both HIV-1 and HTV-2 by the competitive ELISA assays, the type of HIV was 
determined by a peptide-based strip method (PeptiLAV, Diagnostics Pasteur, Mames-La- 
Coquette, France). This technique is based on an immunoenzymatic strip method using two 
mV-specific synthetic peptides which correspond to a type-specific immunodominant 
epitope of the transmembrane envelope glycoproteins :gp41 for HTV-l and gp36 for 
peptide 2. These two peptides are fixed separately on the membrane. If the sample was + 
or -H- for both HIV-1 and HIV-2 bands in PeptiLAV, it was diagnosed as dually 
seroreactive.
2.b.2. Titration of anti-HIV-1 and anti-HIV-2 antibodies.
In Chapter 7, anti-HTV-l and anti-HIV-2 antibody titres were investigated in dually 
seroreactive patients with or without PCR-proven HTV-l and HIV-2 mixed infection.
To determine titres of anti-HTV-l and anti-HTV-2 antibodies, sera were serially diluted in 
ten-fold steps in normal human sera from 1:10 to 1:1000 before testing them with the type- 
specific competitive ELISA assays. The reciprocal value of the highest dilution at which 
ELISA was positive has been taken as titre of antibody.
2.C. PCR-based diagnosis.
The qualitative and quantitative PGR protocol for both HTV proviral DNA and RNA whiSh 
is described here, was developed by Dr N Berry at University College London Medical 
School (Berry et al., 1994 & the manuscript submitted).
2.C.I. Extraction and quantification of cellular DNA.
DNA was extracted from cryopreserved PBMC obtained from heparinised blood using a 
previously described method (Berry et al., 1994). Sample PBMCs were thawed and 
washed once in 1 ml of PBS before being added to PCR-compatible lysis buffer {50mM 
KCl, lOmM Tris-HCl [pH 8.3], 2.5mM MgCk, 0.Img/ml gelatin, 0.4% Nonidet P-40,
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0.45% Tween 20} with proteinase K (200 pg/ml). The volume of lysis buffer was 
determined to give a final concentration of 1x10  ^cells per lOpl of lysis buffer, according 
to the number of PBMCs per vial which was counted by a counting chamber before 
cryopreservation. Lysed cells were incubated at 65°C for 2 hours in a water bath and 
vortexed before another 1 hour of incubation. Residual proteinase K was then inactivated 
by heating the cell lysate at >85°C for 15 minutes. The concentration of DNA in the extract 
was measured by a DNA fluorometer (TK 100 portable fluorometer, Hoefer Scientific 
Instruments, San Francisco USA) with fluorescent staining (Hoechst 33258 dye). The 
concentration was adjusted to a final concentration of 60pg/ml. All DNA samples were 
stored in a deep freezer at.-70°C until its use.
2.C.2. Qualitative PCR for diagnosis of HIV infection.
PCR was conducted using lOpl (0.6pg) of DNA extract which is equivalent to 1 x 10^  cells 
in a primary PCR tube in a total reaction volume of 50pl. For all diagnostic PCR, 
commercialy available PCR buffer {lOmM Tris-HCl [pH 8.3], 50mM KCl} (GeneAmp®, 
Roche Molecular Systems, Inc, Branchburg, New Jersey, USA) was used with 1.5mM 
MgClz, a 200pM concentration of each 2’-deoxynucleoside 5’-triphosphate (dATP, dGTP, 
dTTP, and dCTP) (Pharmacia Biotech), 1 unit of Taq DNA polymerase {AmpliTaq®, DNA 
polymerase, Roche Molecular Systems, Inc, Branchoburg, New Jersey, USA) and lOpmol 
.of each outer primer. For nested PCR, 2pl of the primary PCR product was transferred into 
a secondary PCR tube in a total reaction volume of 25|xl which contains fresh PCR 
reagents and the inner primer set. Outer and inner primer sets which bind HIV-type 
specific but conserved regions in the LTRs were designed and provided by Dr N Berry.
The sequence information is summarised in Table 2.1.
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Hybaid thermocyclers (OmniGene thermal cycler, Hybaid limited  ^Middlesex) were used 
for all experiments. Thermocycling conditions for primary PCR was 94°C/4 minutes for 
dénaturation (1 cycle), 94°C/1 minute of dénaturation, 55°C/1 minute of annealing, 72 C/1 
minute of extension (35 cycles), and 72°C/7 minutes final extension. Thermocycling 
conditions for secondary PCR was 94°/l minute of dénaturation, 50°C/1 minute of 
annealing, 72°C/1 minute of extension (25 cycles) and 72°C/7 minute of final extension. 
PCR conditions for HTV-l and HTV-2 detection were the same except for the primer sets.
Secondary PCR products were run on a 1.5% agarose gel and visualised with ethidium 
bromide. If a single clear band was seen around the expected PCR product size: 141 bp for 
HTV-2 LTR, 120 bp for HTV-l LTR, it was regarded as positive.
To avoid carry-over contamination for PCR diagnosis, the pre-PCR room, equipment, 
gowns, and gloves used for setting the PCR mixture were separated fi-om the DNA 
extraction room, equipment, gowns and gloves used for extracting DNA, and from the 
post-PCR room, equipment, gowns, gloves used for handling PCR products as is 
recommended (Kwok and Higuchi 1989). Positive displacement pipettes with disposable 
capillaries and pistons (Microman®, Gilson Medical Electronics, France) were used to 
load the sample DNA
2.C.3. Qualitative PCR for diagnosis of HTLV-I
PCR conditions for the detection of Human T-lymphotropic virus type I (HTLV-I) provirus 
were the same as that for detection of HTV, except for the annealing temperature which 
was 50°C and the primer sets which specifically bind HTLV tœc/rex region (Table 2.1) 
(Tuke et al., 1992). Since the HTLV primers amplify the tax/rex region of both HTLV 
type-I and type-Tl (HTLV-II), differential diagnosis of HTLV-I and HTVL-II was made by
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restriction enzyme analysis of the PCR product (Tuke et al., 1992) as follows: 5 pi of 
secondary PCR products were digested in a 20pl of reaction mix, containing 10 units of the 
restriction enzyme: Sau3A or Taql, and 2pl of appropriate lOx reaction buffer. Sau3A 
digests were incubated for 90 minutes at 37°C and Taql digests were incubated for 90 
minutes at 65°C. A lOpl aliquot of each digest was analysed by electrophoresis on a 4 % 
agarose gel. If the product was cut to generate a distinct 104 bp and a faint 24 bp (often not 
visible) by Sou 3 A  and cut to yield a 122 bp by Taq 1, the sample was regarded as HTLV-I 
whereas if the product was not digested by Sou 3 A  but cut by Taq 1 to generate a 69 bp 
and a 53 bp, the sample was regarded as HTLV-II.
For each PCR, DNA extracted from C8166 cells (Hahn et al., 1983) and C1218M cell line 
(Clapham et âl., 1984) were included as positive controls for HTLV-I and HLTV-II 
respectively.
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2.C.4. Quantitative DNA PCR
i. Quantification o f HIV-1 and HFV-2 proviral DNA
For quantification of HIV proviral DNA, primary PCR was conducted as described in 
section 2.C.2 except that 5 pi (0.3pg) of DNA extract was used for quantification of HTV-l 
proviral DNA. Ipl of primary PCR product was amplified by a modified seeondaiy PCR. 
The secondary PCR was performed in a reaction volume of 50pl, containing 1 unit of 
recombinant Pfu DNA polymerase (Stratagene, Ltd., Cambridge, U.K.), Pfu DNA 
polymerase reaction buffer {20mM Tris-HCl [pH 8.8], lOmM KCl, lOmM (NH4)2S0 4 , 
2mM MgS0 4 , 0.1% Triton X-100, 0.1 mg/ml nuclease-free bovine serum albumin (BSA)}, 
lOpmol of inner primers of which 5’ end of antisense primer was biotinylated, a 5pM of 
each of the three nucleotides (dGTP, dTTP, and dCTP) and 5pCi of ^ ^S-radiolabelled 
dATP (DuPont, Boston, MA). 30pl of the PCR product incorporated with radiolabelled 
ATP was diluted in a 30pl of PBS/0.05% Tween 20 and captured in streptavidin-coated 
microwells (Maxisorp U16, Nunc, Denmark) which were prepared by coating with 
streptavidin (5pl/ml) in coating buffer {lOmM Tris-HCl, [pH 7.6]} over night, followed by 
blocking with coating buffer containing 0.1% BSA. After incubation at room temperature 
for 45 minutes, the plate was washed thoroughly 10 times with PBS / 0.05% Tween 20. 
Then 0.15M NaOH was added to strip the nonbiotinylated strand of secondary PCR 
product which was counted with the LKB Betaplate counter.
In order to estimate a number of copies of proviral DNA in a patient’s sample, a series of 
external standards containing 3, 15, 80, 400, 2000 and 10,000 HTV-2 provirus copies per 
lOpl of DNA lysate was generated by serially diluting DNA extract from a C8166 cell line 
chronically infected with HIV-2cbl-22 (MRC AIDS Reagent Project, Potters Bar, U.K.) 
with DNA extract from HTV-uninfected C8166 cells for quantification of HTV-2 proviral 
DNA. For quantification of HTV-l proviral DNA, a series of external standards containing
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5, 36, 170, 2100, 10000 HIV-1 provirus copies per 5\û of DNA lysate was made by 
serially diluting DNA extracted from a 8E5 cell line (MRC AIDS Reagent Project, Potters 
Bar, U.K.) with DNA extract from HTV-uninfected C8166 cells. A series of external 
standards were included in each assay and a standard curve was drawn for each experiment 
(Figure 2.3). The number of copies in the standards was determined by limiting dilution 
analysis with nested PCR. Each samples was tested in duplicate, and if the variation in the 
duplicate was ^ 10 fold, the sample was re-tested. On the assumption that the CD4^ cell 
fraction harboured most viruses, the number of proviral copies per 10^  CD4^ cells was 
calculated by dividing proviral copies/10^  PBMCs by CD4^ cell percentage. If the sample 
was positive by qualitative PCR but the proviral copy number was <3 copies, the sample 
was assigned a value of 2.
Inter-assay variation was assessed by including 4 aliquots of the quality control in each 
experiment. Inter-assay variation throughout the experiments was less than two fold. In order 
to avoid the inter-assay variation in the evaluation of viral load change within a patient, all 
samples from one patient were tested in one experiment.
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Figure 2.3. Standard curves for quantitative DNA PCR assays.
Three representative standards curves for HÏV-1 quantitative PCR assay are 
shown in open triangles and for HIV-2 quantitative PCR assay shown in 
shaded squares; c.p.m., count per minute.
ii. Quantification o f HTLV-I proviral DNA
In this study the levels of HTLV-I proviral DNA were analysed by limiting dilution 
analysis as follows: sample DNA was diluted in PCR-compatible DNA lysis buffer {50 
mM KCl, 10 mM Tris-HCl [pH 8.3], 2.5 mM MgCh, 0.45 % NP40, 0.45 % Tween-20} in 
five fold steps using a Gilson positive displacement pipette. Each time the diluted DNA 
was transferred, a new piston and a capillary were used. At each dilution qualitative nested 
PCR was performed with tax/rex primers as described in section 2.C.3. To determine the 
end-point dilution, aliquots of diluted sample around the end-point were tested in 
quadruplicate. If two or more of 4 tests were positive, the dilution was regarded as positive 
and the reciprocal value of the end-point dilution was expressed as titre of HTLV-I 
provirus (copies / 1 pg DNA). In order to investigate the frequency of HTLV-I-infected cells 
in two subjects with an extremely high proviral load, 1.5 x 10^  cells / ml of PBMCs 
suspension was serially diluted in five-fold steps by transferring 200 pi in Eppendorf tubes. 
The diluted cells were spun at 10,000 rpm for 3 minutes and after removing the supernatant 
completely, 150 pi of lysis buffer with proteinase K was added to extract DNA from the pellet 
at each dilution following the method described in section 2.c. 1. The crude DNA lysate of 
each dilution was tested by nested PCR to determine the end-point as described above. To 
ensure the presence of cellular DNA at the end-point dilution, nested PCR for P-glpbin gene 
were applied.
2.C.5. Quantitative RNA PCR
/. Extraction and reverse transcription o f HIV RNA
Viral RNA was extracted from heparinised plasma, which had been stored at -70°C or in 
liquid nitrogen, using a silica-based guanidinium isothiocyanatc extraction method (Boom et 
al., 1990). A 200pl of plasma sample was mixed with SOOpl of lysis buffer f  lOOmM Tris-HCl 
[plj 6.4], 5M guanidinium thiocyanate, 20mM EDTA, Triton X-100} then 50pl of silica was
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added. RNA bound silica was washed five times: (X2) in 5M guanidinium wash buffer 
{lOOmM Tris-HCl [pH 6.4], 5M guanidinium thiocyanate}, (X2) in 70% ethanol, and (XI) in 
acetone. The final silica pellet was dried on a hot-block at 56°C for 10 minutes before eluting 
RNA in 50pl of nuclease-fi-ee water. A lOpl of RNA extract was subject to in vitro reverse- 
transcription (RT) to synthesise first-strand cDNA in a 20pl of reaction volume, containing 
50mM Tris-HCl [pH 8.3], 75mMKCl, 3mMMgC12,0.IMDTT, lOmM of each dNTP, 150- 
200ng per reaction of HIV-2 RT primer which target the primer binding site and its 
immediately upstream in conserved regions (Table 2.2) and 200 units of Superscript II reverse 
transcriptase (Gibco-BRL, Life Technologies). The RT reaction mix was incubated at 45°C 
for 50 minutes.
ii. Detection and quantification o f HIV-2 cDNA
A 5 pi of cDNA was amplified, in duplicate, in a reaction volume of 50pl containing 1 unit of 
Pfu DNA polymerase, Pfu DNA polymerase reaction buffer, 200pM of each dNTP, and 
lOpmol of outer primers for HTV-2 R/U5 LTR (Table 2.2) with 40 heat-cycle {94°C/2 
minutes dénaturation then 94°C/30 seconds dénaturation, 50°C/30 seconds aneal, and 
72°C/30 seconds extension (40 cycles) and 72°C/2 minutes further extension}. For the 
detection of cDNA, secondary PCR was conducted in a reaction volume of 25pi, which 
contains 1 unit of Pfu DNA polymerase, Pfu DNA polymerase reaction buffer, 200pM of 
each dNTP, and 5pmol of inner primers for HIV-2 LTR with 25 heat-cycle {94°C/30 
seconds, 50°C/30 seconds, 72°C/30 seconds (25 cycles) and 72°C/2 minutes}. The product 
was run on a 1.5% agarose gel. If a single clear band was seen around 157 bp, it was 
regarded as positive.
The quantity of PCR product was determined using a chemiluminescence-based enzyme 
linked oligonucleotide assay (ELONA) (Whitby & Garson 1995). A 5 pi of PCR product
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was diluted with 95pl of sample diluent buffer {PBS, 5% casein, 0.5% Tween-20} then 
placed on a streptavidin-coated black plate (Life Science International, Hampshire) to 
capture the PCR product. After being incubated for 45-60 minutes at room temperature, the 
plate was washed five times with TTA buffer {lOmM Tris-HCl [pH 7.5], 0.5% Tween-20, 
0.01% sodium azide}. lOOpl of 0.15M NaOH was added to denature the double strand 
PCR product then the unbiotinylated strand was washed away by five times wash with 
TTA. A single-stranded PCR product was then hybridised with lOOpl of Alkaline 
phosphatase conjugated probe in reaction buffer {lOX SSC, 5% casein, 0.5% Tween-20} 
at 45°C for 60 minutes. Excess probe was removed by washing five times wash with TTA 
before adding lOOpl of substrate Lumi-Phos-530 (I.umigen). After incubation for 1 hour at 
room temperature in the dark, photon emissions were counted by a luminometer 
(Canberra-Packard, UK) or (Luminoskan, Labsystem, Finland).
To estimate the number of RNA copies per ml of sample plasma, external controls were 
included for each assay which were obtained by aliquoting a large stock of plasma samples 
from inV-2-infected patients. The number of RNA copies / ml of external controls was 
estimated by determining the number of cDNA copies by limiting dilution analysis with a 
nested HIV-2 PCR and converting the number of cDNA copies / 5 pi of cDNA to RNA 
copies / ml of plasma, using a conversion factor of 500 (Berry et al., manuscript 
submitted). This conversion factor was derived from repeated measurements of HTV-l 
plasma RNA levels and is based upon the assumption of equal sensitivity for HIV-2 as the 
principle of the tests is the same. The number of cDNA copies / 5 pi of cDNA derived from 
HTV-l plasma samples was determined by limiting dilution analysis using a nested HTV-l 
RNA PCR; the conversion factor was then calculated by dividing the number of HTV-l 
RNA copies / ml determined by a commercial quantitative PCR assay for HTV-l 
(Amplicor, Roche) by the result obtained from the limiting dilution method. Titrated
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plasma controls of 200,000 and 80,000, 20,000 and 2000 RNA copies per ml or 
equivalents were used for each assay and a standard curve was drawn (Figure 2.4). The 
lower level of detectability was calculated to be 500 copies of plasma RNA / ml which 
corresponds to 1 copy of cDNA / 5 pi cDNA. A working cut-off value of 500 copies per ml 
was used. If the sample was positive by nested PCR but less than 500 RNA copies per ml 
by quantitative PCR, the sample was assigned a value of 500. If the sample was negative 
by nested PCR, the sample was assigned a value of 250.
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Figure 2.4. Standard curve for quantitative RNA PCR assay.
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2.d. Cytotoxic T-lymphocyte assay.
2.d.l. Preparation of target cells.
An Epstein-Barr virus (EBV) transformed autologous B lymphoblastoid cell line (BCL) was 
established from each subject and cryopreserved before the use. When the second sample was 
taken for the bulk-culturc, the BCL from the subject was thawed and cultured in RPMI1640 
plus 10% Foetal Calf Serum (FCS)(Life Technologies, U.K.) for at least 7 days. Target cells 
were infected with various recombinant vaccinias expressing the HIV-2 {gag(ROD), 
pol(ROD) or nef(BEN)} genes or VSC8 vaccinia expressing an irrelevant protein (P- 
galactosidase), at a multiplicity of infection of 3:1 for 1 hour and cultured in RPMI 1640 plus 
20% PCS for 16 hours. The cells were labelled with ^^Chromium (lOOmCi Na2 ^^ Cr0 4  
Amersham U.K.) for one hour then washed three times.
2.d.2. Preparation of effector cells.
Fresh PBMCs were separated on Ficoll gradient from 20 ml of preservative free heparin 
treated blood within two hours after the venipuncture. One eighth of the PBMCs were 
stimulated for 24 hours with phytohaemagglutinin(PHA, Wellcome U.K.)(2pg/ml) and 
washed once before being added to the unstimulated PBMCs in order to boost HIV specific 
CTL. This "Bulk culture" was maintained in RPMI1640 plus 10% FCS in a 25cm^ T-flask 
(Cell-cult, Sterilin, U.K.) in an up-right position for 7 days when 10% of Interleukin-2 
(lymphocult T, Biotest, UK) was added. CTL activities were tested at day-7 in 17 subjects 
and at day-14 in all subjects. As responses were highest and most frequent at day-14, these 
results were used in the analysis.
2.dJ. ^^Chromium release assay.
^^Chromium (^^Cr) labelled target cells were plated out at 5000 cells/well in 96 well U- 
bottomed plate (Sterilin, U.K.). In two HIV-2 infected subjects {FI 1, F19} with a low 
CD4%, 2000 target cells/well were used. The effector cells were added in duplicate at 60:1,
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30:1 and 15:1, effector:target (E:T) ratio. Controls for background (target cells with media 
alone) and maximal (with 5% triton X 100) ’^Cr release were plated in quadruplicate. After 
incubating the plate for 5 hours, radioactivity in the supernatant was counted using the LKB 
Betaplate counter. Specific lysis(%) was calculated from the formula:
(experimental count - background) x 100 / (maximal count - background).
The specific lysis(%) to control vaccinia was subtracted from the specific lysis against HTV 
protein to describe HIV-specific lysis. HIV-specific lysis of 10% or more was regarded as 
positive. Background ^^ Cr release was less than 30% of maximal count in all experiments.
2 ,6 . Miscellaneous methods.
2.6.1. CD4/CD8 subset analysis.
Analysis of lymphocyte subsets has been done with fluorescence activated flowcytometry 
(FACScan, Becton-Dickinson, Belgium). For the community-based study in Guinea-Bissau, 
cells in EDTA-treated whole blood were stained with monoclonal antibodies (Becton- 
Dickinson, Belgium); red blood cells were lysed and white blood cells were stabilised and 
fixed using a commercially available reagents (ImmunoPrep, Coulter Electronics Ltd. 
England) and a machine at the field laboratory (Q-Prep®, Coulter). Samples were then 
transferred in a cool box to the main laboratory in The Gambia within a week, where 
FACScan analysis was done. For the hospital-based study in The Gambia, cells in EDTA 
blood were stained with the same antibodies but red blood cells were lysed with 
commercially available lysis reagents (FACS® brand lysing solution, Becton Dickinson, 
Belgium) and fixed with 0.5% formaldehyde.
Due to incomplete erythrocyte lysis and residue of cell debris, some samples were 
occasionally contaminated with a considerable amount of unlysed erythrocytes or debris 
which were counted as cells by FACScan and caused serious underestimate of CD4 and CDS 
count. To minimise this problem, if sum of CD4% and CD8% was less than 45%, the data
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was excluded from the analysis. This verification is particularly necessary when an accurate 
slope of CD4 decline is to be estimated.
Subjects were divided according to the new Center for Disease Control classification into 3 
categories based on their % of CD41 cells' low < 14%, medium 14 - 28%, high > 29% 
(Center for Disease Control and Prevention 1994).
Total white blood cells per pi of blood and percentage of lymphocyte were manually 
determined.
2.6.2. Examination of blood film.
The presence o îPlasmodium falciparum parasitaemia was determined by reading 100 
high-power fields of Giemsa-stained thick blood film by one experienced laboratory 
technician who was masked from all the other laboratory results. If any number of asexual 
P. falciparum was found, the slide was regarded as positive for parasitaemia.
2.6.3. Oth6r laboratory t6sts.
Plasma samples were tested for Treponema pallidum haemagglutining antibodies (TPHA) 
(Microsyph, Porton, Cambridge, Newmarket, U.K.) and for Rapid Plasma Reagin (RPR) 
(Becton Dickinson, Cockeysville). Using commercial tests, active syphilis infection was 
diagnosed if both TPHA and RPR tests were positive.
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Chapter 3.
A community-based study of HIV-2 proviral load in a rural village
in West Africa.
3.a. Introduction.
Previously Berry et al., using quantitative polymerase chain reaction (PCR), reported 
that HIV-2 proviral load in symptomatic patients attending the MRC clinic in The 
Gambia was similar to that of HTV-l-infected symptomatic patients (Berry et al. . 
1994). Another study which used tissiie-culture méthodes, has suggested that the level 
of infectious virus in plasma or cells in HIV-2-infected patients with a relatively high 
CD4 count was lower than that found in similar group of HTV-l-infected subjects 
(Simon et al. 1993). Therefore it was postulated that a low viral load, perhaps as a 
result of high levels of suppressive immunomodulation, may account for the better 
prognosis of HTV-2-infected individuals (De Cock et al. 1993, Marlink et al. 1994). 
However both previously published studies on HTV-2 viral load were hospital-based 
study and HIV-2 viral load in a community-based unbiased HTV-2-infected 
population has not been studied yet.
A community-based study in a rural village in Guinea-Bissau indicated that high 
prevalence of HTV-2 was seen throughout all age-groups including a substantial 
number of old people (> 60 years) and that the majority of infected individuals had a 
CD4% of > 14% and no HTV-related symptoms (Wilkins et al. 1993, Ricard et al. 
1994). Moreover two years of follow-up of these individuals showed that the 
mortality rate among HTV-2 infected individuals was only three-fold higher than that 
in age and sex matched HIV-uninfected individuals and that the mortality rate was not 
different between HTV-2-infected and HIV-uninfected individuals if they were 55 
years or older (TÜcard et al., 1994). This study provided an opportunity to investigate 
HTV-2 proviral load in these healthy HIV-2-infected individuals.
52
3.b. Results.
i  Study subjects.
Between January and May 1991,132 HIV-2 seropositive individuals and 160 age and 
sex matched HTV seronegative individuals were recruited in a prospective cohort 
study in Guinea-Bissau (Chapter 2). Cryopreserved cells were available from 127 
HIV-2 seropositive samples which were initially tested for the presence of HIV-2 
provirus by qualitative PCR; 121 of these positive samples which contained more 
than 5x10^ cells were considered suitable for a quantitative PCR assay. Sixty 
samples were chosen from the controls in order to test the specificity of PCR. The 
population in the study village has been followed with annual censuses, the last being 
conducted in March 1995.
ii Detection and measurement of HIV-2 proviral load
inV-2 proviral DNA was detected in 125 (98.4%) of the 127 seropositive PBMC 
samples by qualitative PCR. Of the two samples which did not contain HTV-2 
sequences, the samples were consistently negative in 20 experiments and the subjects 
have not been included in the analysis. None of the 60 samples from HIV 
seronegative controls were found to contain HTV-2 sequence by nested PCR. The 
geometric mean (95% C.I.) proviral load of the specimens from 121 HTV-2-infected 
subjects which contained at least 5 x.lO  ^cells, was 35.5 (25.7,49.0) proviral copies / 
10^  PBMC. The geometric mean (95% C.I.) proviral load for 104 subjects with valid 
CD4 data was 124.3 (86.0,179.6) copies / 10^  CD4^ cells.
There was a considerable variation in proviral load, ranging from 2.4 to 16045 copies 
/ 10^  CD4^ cells among the study population (Figure 3.1). An inverse relationship 
between proviral load expressed as copies /10^ PBMC or copies / 10^  CD4^ cells and
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CD4% was found (r = -0.22, p = 0.02 or r = -0.42, p < 0.001 respectively). The 
geometric mean (95% C.I.) for subjects with high (> 29%), medium (14 - 28%) or 
low (< 14%) CD4% was 85.2 (51.9,140.1) (n = 55), 166.6 (94.9, 292.3) (n = 46) and 
1385.7 (86.1,22,311.1) (n = 3) proviral copies / 10^  CD4^ cells respectively.
m  Proviral load in relation to age
No significant trend was noticed between age and the number of proviral copies /10^ 
CD4^ cells (r = -0.06, p = 0.5). Proviral load was stratified into three age-groups. The 
geometric mean (95% C.I.) proviral load of those less than 40 years, those 40 - 59 
years and those > 60 years was 151.8 (66.2, 348.3) (n = 26), 113.8 (71.1,181.9) (n = 
48) and 120.3 (52.0,278.4) (n = 30) proviral copies / 10^  CD4+ cells respectively. 
Considerable variation was observed in all age-groups and the mean viral load was 
not significantly different in three age groups (Figure 3.2).
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Figure 3.2. HTV-2 proviral load in three age groups.
Geometric means and 95% confidence intervals are indicated by 
horizontal bars; the eleven subjects who died are indicated by 
the shaded square dots.
rv. Proviral load in relation to co-infections
Many subjects were also infected with active syphilis, malaria or HTLV-L Active 
syphilis was diagnosed by TPHA and RPR serology, malaria infection by Giemsa- 
stained thick blood film, and HTLV-I infection by a nested PCR with restriction 
enzyme analysis. Typing of restriction digests of PCR products showed that all HTLV 
PCR positive samples were HTLV-I (Figure 3.3). The subjects were stratified 
according to the presence or absence of co-infection and the mean proviral load in 
each group is shown in Table 3.1. Proviral load did not differ significantly according 
to co-infection.
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Figure 3.3. Restriction enzyme analysis of HTLV-I/II tax/rex PCR products.
Agarose gel (4%) electrophoresis of Taq 1 and &zw3a digests of secondaiy PCR products 
stained with ethidium bromide is shown. The upper half of the gel was loaded with Taq\ 
digests, the lower half with Sau?>dL digests. Reading from left to right, lane 1 contains digests of 
products derived from HTLV-I positive control (C8166), lane 2 contains digests of products 
derived from HTLV-II positive control (C1218M), lanes 3 to 7 contain digests of products 
from samples c32, c33, c67, c68, and c86. The extreme right lane carries the molecular-weight 
marker, phiXl lAIHaelW digest (the lowest two bands of the molecular weight ladder are 118bp 
and 72bp). The rest of samples showed the same pattern.
Presence of infection Absence of infection
Syphilis 142.2(67.6,299.2) 120.2 (78.0,185.4)
(n) (20) (84)
Malaria 102.8(36.8,287.1) 145.5(96.4,219.8)
(n) (18) (80)
HTLV-1 131.8(75.0,231.7) 122.2(77.4,192.8)
(n) (23) (81)
Table 3.1.
Effects of co-infection with active syphilis, malaria and HTLV-I on HIV-2 proviral load.
Geometric means (95% confidence interval) copies / 10^  CD4^ cells are shown.
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V. Pro viral load in relation to mortality
Since the start of the cohort study until March 1995,6 out of the 104 subjects with 
valid CD4 data had moved from the village, 87 subjects still lived in the village and 
11 have died. The six subjects who moved have been excluded from the mortality
analysis. Mean (range) duration of follow-up among subjects who died was 580 (29 -
\
1328) days. The age adjusted geometric mean (95%C.I.) proviral load of 11 subjects 
who died was 654.2 (181.9, 2352.2) copies /10^ CD4+ cells which was significantly 
higher than that of 87 subjects who survived which was 104.1 (70.4,153.9) copies / 
10^  CD4+ cells (p = 0.003). The age adjusted mean (95% C.I.) CD4% of those who 
died was 19.5 (13.2,25.9)% which was significantly lower than that of the survivors 
which was 30.3 (28.3,32.3)% (p < .001). The subjects were stratified into four 
categories according to their proviral load and CD4% (Figure 3.1). Nine out of 28 
subjects in category-I ( > 100 copies /10^ CD4+ cells and CD4% < 29%) died 
compared to 0/20 in category-II (>100 copies /lOf CD4+ cells and CD4% > 29%), 
1/20 in category-in ( < 100 copies / 10^  CD4+ cells and CD4% < 29%), 1/30 in 
category-IV ( <100 copies / 10^  CD4+ cells and CD4% > 29%). Age and sex adjusted 
odds ratio (95% C.I.) between the mortality in category-I and the other categories was
I
32.5 (4.0,263.8) (p <0.001). Thus the mortality rate was significantly higher in 
category-I than that in the other categories. The exact cause of death could not be 
ascertained in any of the subjects who died.
3.C. Discussion
No other study has related viral load to mortality in HIV-2 infection. This study first 
showed that a high proviral load and a relatively low CD4%, but not a relatively low 
CD4% or a high proviral load alone, was related to mortality. Most studies of viral 
load have been based on patients attending hospital thus the real picture of viral load 
in a community setting is lacking. In this village, apart from an increased presence of
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lymphoadenopathy in cases, there were no clinical differences between the HTV-2 
infected cases and uninfected controls (Ricard et al. 1994). Thus the study population 
were generally asymptomatic. However the level of HTV-2 proviral load varied 
considerably and the mean was found to be high, even in the subjects with a high 
CD4% of > 29%. Previously published studies using quantitative PCR have shown 
that among asymptomatic HFV-1-infected individuals the mean level of HIV-1 
proviral load was around 50 copies /10^ PBMC or 100 copies / 10^  CD4+ cells (Ferre 
et al. 1992, Bieniasz et al. 1993, Chervert et al. 1994). Hence the level observed in 
healthy HTV-2-infected villagers appears to be similar to that found in HIV-1-infected 
asymptomatic individuals, although there is no comparable community-based viral 
load study of HIV-1 from Africa.
These findings of HIV-2 proviral load do not support the previous hypothesis that 
asymptomatic individuals infected with HIV-2 live longer because they have a lower 
viral load than HTV-1 infected individuals (Simon et al. 1993). Hence the level of 
proviral load per se may not be the only factor accounting for the better prognosis of 
HTV-2 infection. STVagm can be consistently isolated from its natural host, the 
Afiican Green Monkey, which does not suffer from immune deficiency even though 
it has a viral load of 5 - 50 copies / 10^  PBMC (Hartung et al. 1992). Likewise HTV-2 
may develop a similar relationship to its host, so that the provirus can be maintained 
at a substantial level without destroying the immune system and killing the host as 
fast as that observed in HTV-1 infection. As proviral load measures both productive 
and latent infection, one explanation may be that in HTV-2 infection more CD4^ cells 
are latently infected and fewer are actively producing viruses than in HTV-1 infection. 
This may result in a slower rate of destruction of CD4^ cells for recent studies have 
shown that the virus-producing cells are killed within a much shorter period than 
latently-infected cells (Wei et al., 1995; Ho et al., 1995). Alternatively in HIV-2
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infection a larger proportion of proviral genomes may be defective than in HTV-1 
infection. It has been planned to measure the level of HIV-2 RNA in plasma, which is 
a better index of productive infection than proviral load, and may be important in 
understanding the differences in the pathogenesis of the two infections. The level of 
HIV-2 RNA in plasma and its relation to the disease progression are studied in 
^Chapter 4.
Other infectipus diseases which are common in the tropics were investigated to test 
whether they influenced proviral load. The data did not show any significant effect of 
malaria, active syphilis or HTLV-I co-infection on HTV-2 proviral load. However 
since malaria parasitaemia is thought to be transient and because most villagers have 
intermittent parasitaemia, it would be difficult to demonstrate the effect of malaria on 
proviral load. The effect of HLTV-I and malaria co-infection is discussed again in 
Chapter 6.
The time course of the HTV-2 epidemic in this comniuniiy and duration of HIV-2 
infection in an individual subject are matters of speculation. However it is reasonable 
to assume that on average the duration of infection in the old subjects is longer than 
that in the young subjects. In this study we noted that the mean proviral load in the 
older age group (>60 years) was not significantly higher than that of the younger age 
group (under 40 years). Presuming that the virus in the older age group is as equally
I
replication-competent as that in the younger age group, this suggests that in this 
population the proviral load of HIV-2 does not increase significantly with time. This 
may be a reflection of the better prognosis of HTV-2 infection.
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3.d. Discussion of the 1996 follow-up survey
According to the most current census survey conducted in 1996, 6 more HTV-2-infected 
subjects died during 1995. Of those, HIV-2 proviral load data in 1991 was available in 4 
subjects. On the contrary to the initial expectation, there was only one more death in the 
category of a high proviral load and a low CD4 count (Category-I); the rest of 18 subjects in 
this category have survived during the five years of fpllow-up. One subject who died, had a 
high proviral load and a high CD4 count (Category m) and two other subjects who died, had 
a low proviral load and a high CD4 count (Category IV) in 1991. These subjects may have 
had an increase in proviral load which caused the deaths. However since 7 deaths were 
notified among HIV-uninfected controls during 1995, which is more than the number of 
deaths among HTV-2-infected cases during the same period and also a similar cohort in 
Bissau showed that the mortality rate ratio decreased over-time (Poulsen et al., 1997), deaths 
observed later in the cohort may not be directly related to the HTV-infection.
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Chapter 4.
Plasma RNA viral load predicts the rate of CD4 decline and death in HTV-2 infected
patients in West Africa
4.a. Introduction.
Dichotomy in the rate of HIV-2-disease progression exists and it is important to investigate 
what factors determine the difference in the rate of disease progression (Chapter 1).
Chapter 3 demonstrated that subjects with a high HIV-2 DNA load with a low CD4 count 
were more likely to die. However the 1996 follow-up data showed that several HTV-2- 
infected individuals with a high level of provirus, survived for long. As was discussed in 
general, introduction, the level of provirus in peripheral blood lymphocytes does not 
necessarily reflect the rate of viral replication which is more directly reflected by the level 
of viral RNA in plasma. Later a number of papers have demonstrated that RNA viral load 
is a strong prognostic marker ofHTV-1 disease progression (Mellors et al., 1995, 1996; 
Henrard et al., 1995; Phillips et al., 1996; Ruiz et al., 1996; de Wolf et al., 1997). Thus the 
measurement of plasma HTV-2 RNA viral load is essential to understand the pathogenecity 
of HTV-2. Recently Berry et a l, have developed an assay to measure HIV-2 RNA viral 
load in plasma and found in a cross-sectional observation that HTV-2 RNA load inversely 
correlated with CD4^ count (Berry et a l, manuscript submitted). However the study did 
not relate HTV-2 RNA viral load with the disease outcome. Therefore this chapter 
examines whether Hiy-2 RNA viral load is a better predictor for the rate of disease 
progression than HIV-2 DNA load. Since no longitudinal observations of HIV-2 RNA and 
DNA viral load over time have been reported, DNA and RNA viral load wei'e 
longitudinally determined and compared between HIV-2-infected long-term slow/non- 
progressors and fast progressors.
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4.b. Results. 
i  Study subjects.
All study subjects were recruited from the clinical cohort at the MRC hospital, Fajara 
which is described in Chapter 2. From January 1991 to December 1992, 184 HIV-2 
seropositive subjects who attended at the MRC hospital, were tested for CD4 and CD8 
counts; 133 subjects had a CD4 > 14% at the base line. The first sample collected during 
the first two years was used to measure base-line viral load. Since the aim of the first part 
of this chapter is to correlate HTV-2 viral load in earlier stages of infection with CD4 
decline and the disease outcome, those patients with a base-line CD4%<14% or had less 
than three validated CD4 data or less than one year follow-up were excluded from the 
study. In June 1995 when the study to compare base-line HTV-2 proviral load with CD4 
decline was closed, 38 subjects were selected as they had met the criteria for inclusion to 
this study: a base-line CD4% >14%, at least three validated CD4 data, and more than one 
year follow-up. In 1997 when an HTV-2 quantitative RNA PCR assay became available, 
the base line plasma samples of these 38 subjects were tested for RNA viral load. The 
mean slope of CD4% for each patient was determined by applying a linear regression line, 
assuming that CD4% decline linearly during the study period (Jaffar et al., 1997). In order 
to extend the period of follow-up, all available CD4% data and survival data up to March 
1997 were used for this analysis. In order to observe HTV-2 RNA and DNA viral load 
longitudinally, 4 long-term slow/non-progressors were selected based upon the following 
criteria: those with CD4% remaining normal (>28%) and without HIV-related symptom for 
over 2500 days since HTV-infection was first diagnosed. Five fast-progressors were 
selected b^ed upon criteria: those with CD4% decline faster than - 4% per year. Two of 
the long-term slow/non-progressors and two of the fast progressors who were recruited for 
this longitudinal observation after June 1995 have not been included in the over all 
analysis.
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a  Characteristics of Subjects,
The characteristics of the 38 subjects are summarised in Table 4.1. The subjects have been 
grouped according to their base-line DNA or RNA load in order to facilitate Kaplan-Meier 
survival analysis. The chdracleristics of selected 4 long-term slow/non-progressors and 5 
fast-progressors are shown in Table 4.2.
Hi Base-line viral load in relation to CD4% slope
First, the relation between a base line HIV-2 viral load and a subsequent CD4 decline was 
analysed. Figure 4.1.a. shows that there was a significant inverse correlation between the 
base line RNA viral load and the subsequent CD4 decline (r=; - 0.36, p=0.027). The rate of 
CD4 decline per year increases by - 1.472 CD4% for each logio increase in RNA viral load. 
However there was no significant relation between the base line DNA viral load and the 
subsequent CD4 decline (Figure 4.1.b) (r= - 0.19, p=0.26).
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Figure 4.1. Comparison between HIV-2 viral load and CD4^ cell decline.
The rates of CD4 decline (% per year) in 38 HIV-2-infected subjects are plotted in relation 
to their base line RNA (Figure 4.1 .a) or DNA viral load (Figure 4.1 b)
IV. Survival analysis
The relation between survival and base line viral load when considered as a continuous 
variable was analysed using the Weibull regression model which assumes that the chance 
of death increases smoothly with time. After adjusting for CD4% and age; a strong 
correlation between survival and the base line RNA viral load was found, the Hazard ratio 
significantly increases at the rate of 3.01 (95% IC 1.5, 6.1) for each logio increase in RNÀ 
viral load (p=0.002). The relation between survival and the base line DNA viral load was 
also significant but less strong; the Hazard ratio increase at the rate of 3.64 (95% Cl 1.2, 
10.8) for each logio increase in DNA (p=0.02).
Kaplan-Meier survival estimates for each band of RNA and DNA viral load were also 
plotted in Figure 4.2.a. and 4.2.b. A clear difference in survival rate was noticed between 
the group with a low RNA viral load (<500 copies / ml) and the group with a high RNA 
viral load (>50,000 copies / ml): the hazard ratio between these groups after adjusting for 
base-line CD4% and age was 52.3 (95% Cl, 5.6, 483.3; p<0.0001). However the hazard 
ratio between the groups with a low and a medium RNA viral load (500 - 50,000 copies / 
ml) was not significant, being 3.1 (95% Cl 0.53, 18.6) (p-0.21). When analysing the DNA 
viral load data, survival rates were not significantly different between the groups with a 
low DNA viral load (<50 copies /10^ PBMC) and the group with a medium (50-500 copies 
/ 10^  PBMC) or a high DNA viral load (>500 copies / 10^  PBMC). After adjusting for 
CD4% and for age, the hazard ratios between the groups with a low DNA viral load and 
with a high DNA viral load was 5.0 (95% Cl 0.60, 41.8; p=0.14).
At least two deaths in the group with a low RNA viral load and one death in medium RNA 
viral load group were caused by HIV-unrelated disease: one was due to congestive heart 
failure and two due to hepatoma. Of those with a high HIV-2 RNA viral load, five patients 
have died within four years. All five appeared to have died with HTV-related diseases: 
three with recurrent chest-problems, one with septicemia and one AIDS which was 
diagnosed two years prior to her death.
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Figure 4.2. Kaplan-Meier survival analysis of 38 HIV-2-infected subjects according to 
RNA and DNA viral load.
V. Longitudinal observation o f RNA and DNA viral load.
Profiles of CD4% and RNA and DNA viral load of 5 fast-progressors and 4 long-term 
slow/non-progressors are shown in Figure 4.3 and 4.4. Both RNA and DNA viral load are 
consistently high in the 5 fast-progressors and consistently low in the 4 long-term 
slow/non-progressors. The rate of CD4% decline and the mean RNA and DNA viral load 
in each fast-progressors and long-term slow/non-progessors are summarised in Table 4.2. 
The means of mean RNA and DNA viral load among 5 progressors were 156,121 ' 
copies/ml and 9,137 copies/10^ CD4^ cells respectively. These were more than two log 
higher than the means of mean RNA and DNA viral load among long-term slow/non- 
progressors which were 395 copies/ml and 17 copies /lO^ CD4^ cells respectively.
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Figure 4.3. Profiles of CD4%, RNA, and DNA viral load of 5 fast-progressors
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Figure 4.4. Profiles of CD4%, RNA, and DNA viral load of 
4 long-term slow/non-progressors.
4.C. Discussion
The data demonstrates that a base-line HIV-2 RNA load significantly predicts the rate of 
disease progression as determined by CD4^ decline or death but that base-line HIV-2 DNA 
load is a less sensitive predictor. This observation is compatible with conclusions drawn 
after a number of studies on HIV-1 viral load (Mellors et al., 1995,1996; Henrard et al., 
1995; Phillips et al., 1996; Ruiz et al., 1996; de Wolf et al., 1997) and implies that the 
mechanism of HIV-2 pathogenesis is similar to that of HTV-l. Therefore like HIV-1, a 
rapid decline of CD4^ cell count is likely to be associated with a high rate of HIV-2 
replication and a rapid turn-over of HIV-2 productively infected cells. The association 
between HIV-2 DNA load and the rate of disease progression was less obvious as some 
subjects had had relatively high levels of HIV-2 provirus for the low level of HIV-2 RNA 
in plasma. Perhaps in these individuals the majority of HIV-2 provirus was in a 
unintegrated form which is replication incompetent as has been demonstrated in HIV-1 
(Chun et al., 1997).
There is a general view that HIV-2 infected individual progresses slower than HTV-l 
infected individuals (Poulsen et al., 1989, 1997; Ridard et al., 1994; Whittle et al., 1994; 
Marlinks et al., 1994). However five HIV-2 progressors are described in this chapter who 
had had a high RNA viral load throughout the observation and a very rapid CD4% decline. 
As seroconversion time of the 5 HIV-2 fast-progressors was not known, the true length of 
HTV-2 infection is only speculative. However the mean age among the group with a very 
high RNA load (> 50,000 copies /ml) was not significantly older than the other groups 
(Table 4.1) and at least three fast-progressors who are described in detail in Table 4.2 and 
Figure 4.3, were relatively young: 20, 26 and 35 years old. Therefore some of HTV-2 
progressors are truly fast-progressing HTV-2 patients rather than those who started to 
progress as a consequence of longer incubation period of HTV-2 infection.
75
Four long-term slow/non-progressors with little evidence of CD4% decline were also 
identified and their RNA viral load were followed longitudinally. During the observation 
period of over 2500 days, RNA viral load was found to be consistently low as has been 
observed in HTV-l long-term non-progressors (Chapter 1). This indicates that HTV-2 
infected slow/non-progressors have established a steady relationship with the virus at a low 
rate of HTV-2 replication and this steady state relationship is one of the mechanisms which 
dictate a better clinical outcome in HTV-2 infection.
The reason for this dichotomy in the rate of HTV-2 replication and the rate of disease 
progression remains largely unknown. Vmous virological factors have been postulated 
including:, biological properties of HTV-2 such as in vitro virus replication and syncytia 
forming properties (Albert et al., 1990a; Schulz et al., 1990), chemokine receptor usage 
pattern may also be important as HTV-2 primary isolates fi-om one of a fast-progressor were 
found to use broad chemokine receptors such as CCRl, CCR2b, CCR3, CCR4, CCR5 and 
CXCR4 (McKnight et al., manuscript submitted), HTV-2 viral genotype may be linked to 
mortality in a community-based study in a rural village (Crassly et al., manuscript 
submitted). Various host factors have also been postulated: HTV-2 specific cytotoxic T- 
lymphocyte (CTL) activities (Gotch et al., 1993; Chapter 5), neutralising antibodies (NA) 
against autologous viruses (Bjorling et al., 1993). Perhaps the host-virus inter-relationship 
must be important for determining the rate of disease progression. Therefore if certain 
individuals are infected with a certain viral genotype, it causes disease but the same strain 
does not necessarily cause disease at the same rate in different individuals.
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Chapter 5.
HIV-2-Specific Cytotoxic-T-Cell activity is inversely related to proviral load 
5.a. Introduction.
Cytotoxic T-cells (CTL) are thought to play an important role in controlling various 
viral infections (reviewed by McMichael & Walker, 1994). In chapter 1, it is 
discussed that in most HEV-l-infected asymptomatic individuals CTL can be 
demonstrated against the structural proteins Env, Gag and Pol and that the precursor 
frequency of HIV-1-specific CTL is unusually high in such individuals (Hoffenbach 
et al., 1989; Gotch et al., 1990; Carmichael et al., 1993). On the other hand it has been 
postulated that excess CTL activity may contribute to the immunopathogenesis of 
AIDS (Zinkemagel & Hengartner, 1994; Koenig et al., 1995).
CTL in HTV-2 infection has not been investigated as intensely as in HIV-1 infection. 
HIV-2-infected individuals live longer than HIV-1-infected individuals (Chapter 1). 
Thus research into the immune mechanisms which account for these differences may 
provide a more general insight into the pathogenesis ofHTV disease. Therefore this 
chapter has investigated CTL activities against various HTV-2 viral proteins at 
different stages of HTV-2 and HIV-l/HTV-2 dual infection using autologous target 
cells and related them to HTV-2 proviral load.
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5.b. Results 
i  Study subjects
Twenty HTV-2 seropositive subjects and 4 subjects seropositive for both HTV-1 and 
HTV-2 were recruited from the hospital-based study in The Gambia. Their clinical 
status is shown in Table 5.1. None of the study subjects were suffering from an acute 
disease at the time of evaluation except for subject FI 9 who had fever, which was not 
due to malaria or bacteraemia. All subjects were tested for CTL between 20th January 
and 8th April 1994 during the dry-season when clinical malaria in adults is rare.
iLHIV-2 specific CTL activities
CTL responses against HIV-2 Gag, Pol and Nef protein in 16 HTV-2 seropositive, and 
4 HIV-l/HTV-2 dually seropositive individuals after day-14 of culture are shown in 
Table 5.1. A CTL response with a HTV-specific lysis of >10% to Gag or Pol protein 
was seen in 18/20(90.0%) or 14/20(70.0%) of the subjects respectively whereas a 
CTL response against Nef protein was apparent in only 5/20 (25.0%) individuals. 
Fifteen subjects had a CD4% of > 14%. All of these subjects recognised at least one 
HTV protein with a HTV-specific lysis of ^  10%; 10 (66.6%) showed a HTV-specific 
lysis of > 10% at two E:T ratios. Fifteen of the subjects were asymptomatic. All 
asymptomatic subjects regardless of their CD4%, responded to at least one of the HIV 
proteins; 13 (86.6%) showed a HTV-specific lysis of > 10% at two E:T ratios. In 
14/20(70.0%) subjects multiple HIV proteins, usually Gag and Pol, were 
simultaneously recognised.
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üi Comparison of CTL activities and HIV-2 proviral load:
In order to examine the relationship between HTV-2 specific CTL activity and HTV-2 
proviral load, HIV-specific lysis (%) of day-14 culture at an E:T ratio of 30:1 was 
taken as a representative quantitative value. The coefficients of correlation between 
HTV-specific lysis to each HIV-2 gene and the HTV-2 proviral load expressed as 
copies/10^  CD4^ cells among 16 HIV-2 seropositive subjects and 4 HTV-l/HIV-2 
dually seropositive subjects are shown in Table 5.2. Significant relationships were 
found between viral load and Gag-specific CTL or, to a less extent, Pol-specific CTL 
(p<0.05), but not to Nef-specific CTL. Total HTV-2-specific CTL activity was 
calculated as the sum of HTV-specific lysis (%) against three target genes: a strong 
relationship between the sum of HTV-specific lysis and the viral load was found 
(Table 5.2, Figure 5.1. A). In 11/19 (57.9%) of subjects who significantly recognised 
HIV-2 proteins, the highest HTV-specific lysis was against Gag protein. In 7/19 
(43.8%) of subjects, the highest HIV-specific lysis was against Pol protein and in 1/19 
(5.3%) against Nef protein. When the highest specific lysis was regarded as dominant 
CTL activity, there were even stronger relationships found between HTV-specific 
lysis of the dominant CTL and viral load (Table 5.2, Figure 5.1 .B). A weak but non­
significant correlation between CD4% and dominant CTL activity was noted (Table 
5.2). There was no significant relation found between CD4^ cell count, CD8% or 
CD8^ cell count and HIV-specific lysis (data not shown).
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5.C. Discussion
HIV specific CTL may be presented by multiple class IHLA molecules (McMichael 
& Walker, 1994). Thus in order to analyse the total CTL activity, autologous target 
cells were utilised in our assay.
Significant HIV-2-specific CTL against Gag and/or Pol proteins was demonstrated in 
the majority of the study subjects especially if they had a CD4% >14% or if they were 
asymptomatic. Similar observations have been made in HTV-l infected asymptomatic 
individuals (Walker et al., 1988; Nixon et al., 1988; Lamhamedi-Cherradi et al.,
1992). The demonstration of significant HIV-2-specific CTL in most ofHTV-2- 
infected individuals suggests that the better prognosis of HFV-2-infected individuals is 
not due to absent or low CTL activity with consequent sparing of CD4+ cell 
destruction, as suggested in the hypothesis of Zinkemagel RM. and Hengartner 
H.(Zinkemagel & Hengartner, 1994).
It was also noticed that in many subjects multiple HTV proteins were simultaneously 
recognised. Whether CTL against one target protein is sufficient to suppress viral 
replication or whether CTL against multiple HTV proteins work synergistically to 
control the vims replication remains unknown. Individual target-specific CTL activity 
did not have as strong a relation to viral load as the sum of CTL activity against three 
targets. However it is noteworthy that when the dominant CTL activity was plotted 
against viral load the best inverse correlation was seen. This observation suggests that 
the dominant CTL against any one of target proteins may be particularly important for 
suppressing viral replication. The infi-equent recognition of Nef by CTL in our study 
subjects may have been due to sequence variation between the Nef gene in the 
recombinant vii us, which was derived fi'om HIV-2ben and Nef gene in the wild-type 
vims prevailing the Gambia. The wild-type vims may relate more closely to HIV-
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2 r o d  from which gag and/ x ? / target genes were originated. Alternatively infrequent 
recognition ofNef by CTL may be characteristic of HIV-2 infection.
The use of specific lysis in bulk-culture to quantitate CTL activity is generally 
considered to be less accurate than limiting dilution analysis(LDA) (Carmichael et al.,
1993). However Gallimore et al. have recently shown a clear correlation between 
precursor frequency determined by LDA and specific lysis by a bulk culture after 14 
days at 30:1 E:T ratio (Gallimore et al., 1995). Also the LDA method suffers from a 
number of problems, in particular how to arbitrarily define the cut off between 
positive and negative responses, and how to deal with nonspecific background lysis. 
In order to standardise this test, the conditions of the bulk culture, the day when the 
bulk culture was tested and the E:T ratio were strictly controlled. The data was also 
analysed using the specific lysis at 15:1 or 60:1 or the mean specific lysis of three E:T 
ratios to express CTL activity quantitatively. Whichever value was used, a significant 
relation between the HIV-specific lysis and viral load was seen (p<0.05). Although 
HIV-specific lysis was lower in day-7 cultures, this measurement was also 
significantly and inversely correlated to proviral load (data not shown). Thus this data 
provides evidence to support the hypothesis that HIV-2-specific CTL play an 
important role in controlling HIV-2 replication.
Proviral load, which is a direct measure of the number of both latent and productive 
infection in cells, seems relatively slow to chaiige (Perelson et al., 1997). On the other 
hand plasma viral load appears to be an index of the number of cells producing 
viruses; the turnover of productively infected cells, which is very rapid, might be 
responsible for the pathogenesis of AIDS (Chapter 1). It would be interesting to relate 
plasma viral load to CTL activity, since CTL are likely to be directed primarily at 
cells actively producing viruses. Nonetheless in this study a clear relationship was
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observed between CTL activity and proviral load, implying that the virus-CTL 
relationship in HIV-2 infection may have reached a steady state where the dominant 
CTL may be directed against conserved regions of the virus (Nowak & Bangham, 
1996). In HIV-1 infection, one study found that there was an inverse relationship 
between HIV-1 Env-spceific CTL activity and proviral load (Kundu & Merigan,
1994) but another study did not find such a correlation (Rinaldo et al., 1995b). The 
virus-CTL relationship in HIV-1 infection may differ where the dominant CTL may 
target more variable regions of the virus.
There was one subjects (F16) who had low viral load of less than 10 copies/10^CD4^ 
cells but had relatively low CTL activities. The first CTL results of subject F16 may 
not be accurate because of a high background of^^Cr release (^5%). However in the 
second experiment, 2 years after the first experiment, the subject was found to have a 
very strong CTL activity against Gag (Figure 5.2). It was also noticed that there were 
several subjects {F3, F4, F6, F14} with HIV-2 single infection who had high viral 
load of >100 copies/10^CD4‘" despite high CTL aaivity of significant lysis at least 
two E:T ratios. As previously argued in HTV-l infection (Phillips et al., 1991), mutant 
viruses may have emerged in the subject and escaped the CTL check.
S.e. Longitudinal observation of HIV-2-specifîc CTL.
Although the first part of this chapter demonstrated a gross correlation between a 
proviral load and the CTL activities, the study subjects were a mix of early stage and 
late stage of either HIV-2 single or HIV-l/HIV-2 dual infection. Of interest was to 
compare HTV-2-specific CTL activities longitudinally among HTV-2 singly infected 
individuals with a relatively high CD4% (^0% ) particularly between those with a 
low proviral load (<15 copies / 10^  CD4^ cells) and with a high proviral load (>100 
copies /10^ CD4^ cells). CTL activities have been repeatedly measured in 5 subjects
8 6
with a low proviral load (F21, Fl2, F22, F16, F38} and 3 subjects with a high 
proviral load {F6, F14, F3 }, over the following two years. As Gag CTL dominated 
among these subjects, HIV-2-Gag specific CTL activities during the three years of 
follow-up are shown in Figure 5.2. Subject F4 was excluded fi-om the analysis as the 
subject was also infected with HIV-1. The 5 subjects with a low proviral load were 
found to have a strong CTL throughout the period of observation whereas the 3 
subjects with a high proviral load despite a singificant level of CTL in first year of the 
study, were found to have a low level of CTL activities in third year of the study. 
These observations suggest that the virus-CTL relationship is stable among HTV-2- 
infected long-term non-progressors where a high level of CTL is maintained perhaps 
by a low level of viral antigen presentation. On the other hand, among progressors the 
virus-CTL relationship is not stable as CTL activities tend to fluctuate. Interestingly 
in such progressors an increase in viral load precedes the decline of CTL activities. As 
it was shown in animal experiments, over-presentation of viral antigen may have 
induced anergy (Rocha et al., 1993). Alternatively a high rate of viral replication may 
have impaired CD4^ T cell function which is required for maintenance of CTL 
activities, as it was reported that cytomegalovirus-specific helper cells are needed to 
maintain cytomegalovirus-specific CTLs (Walter et al., 1995).
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Effects of various co-infections on HIV-2 viral load
Many infectious diseases are more common in Africa than in the developed countries. 
Thus HIV-infected individuals living in Africa are more likely to be exposed to and 
co-infected with other infectious diseases. Several co-infections and immunogens 
such as influenza virus (Ho et al., 1992), herpes simplex virus-1 (Heng et al., 1994), 
M ycobacterium  tuberculosis (Goletti et al., 1996), and bacterial pneumonia (Bush et 
al., 1996) and vaccination (Staprans et al., 1995; Stanley et al., 1996) have been 
shown to increase HIV-1 replication. In this chapter, the effect o f  HTLV-I and 
malaria has been studied.
6.a. Lack of in vivo evidence for the enhancement of HIV-2 infection by HTLV-I.
6.a.l. Introduction.
Both Human Immunodeficiency Virus Type-2 (HIV-2) and Human T-Lymphotrophic 
Virus Type-I (HTLV-1) are endemic in West Africa (Pepin et al., 1991a; Naucler et 
al., 1992; Biggar et al., 1993; Dada et al., 1993; Hishida et al., 1994; Norrgren et al., 
1995; Chapter 3). The viruses are transmitted horizontally through sexual intercourse 
or contaminated blood or vertically from mother to child and both establish a 
persistent infection (reviewed by Centers for Disease Control and Prevention, 1993). 
Risk factors for infection are shared by the two retroviruses, consequently individuals 
who harbour one virus, may often be co-infected with the other virus (Pepin et al„ 
1991a, Naucler et al., 1992; Bigger et al., 1993; Norrgren et al., 1995). At the cellular 
level, both viruses infect CD4 lymphocytes thus there may be co-infection o f  the 
same host cell in vivo  (Richardson et al., 1990). In vitro experiments have suggested 
several direct and indirect mechanisms by which HTLV-1 may augment the level o f  
HlV-1 replication although only few  studies have been performed for HIV-2 (Zack et 
al., 1988; Lusso et al., 1990; Sakai et al., 1990, Lewis et al., 1990; Landau et al.,
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1991; McGuire et al., 1993). Evidence is accumulating to show that increased HTV^l 
replication is responsible for CD4 decline (Chapter 1). Thus co-infection with HTLV- 
I has also been thought to enhance the rate of HIV disease progression by increasing 
HTV virus replication. Nonetheless little is known about HTV virus load among those 
infected with both HTV and HTLV-I and despite several clinical studies, it is still 
controversial whether HTLV-I co-infection influences the course of HIV disease 
(Page et al., 1990; Murakami et al., 1991; De Rossi et al., 1991; Visconti et al., 1993; 
Schechter et al., 1994).
The overall genetic diversity of HTLV-I within a carrier is less than that of HIV-1 or 
HIV-2 (Gessain et al., 1992; Wattel et al., 1995). However the level of HTLV-I 
provirus has been found to vary remarkably being up to 100,000 fold different 
between infected individuals (Gessain et al., 1991; Matsumura et al., 1993). This 
variation in the level of HTLV-I provirus in carriers may be important in the 
pathogenesis of HTLV-I infection and its interaction with HTV disease. HIV-2 
proviral load has been investigated in a rural village of Guinea-Bissau where HIV-2 is 
endemic and a high prevalence of HTLV-I infection was also found (Chapter 3). 
However the study did not show a significant difference in the geometric mean HTV-2 
provirus load between those with and without HTLV-I infection. It was postulated 
that the effect of HTLV-I co-infection on HTV disease or HTV replication may vary 
according to the level of HTLV-I virus load. Thus in this chapter HTLV-I provirus 
load was determined in these villagers and was related to HTV-2 provirus load, and 
conversely assessed the effect of HTV-2 infection on HTLV-I provirus load.
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6.a.2. Results 
L Study subjects
As described in Chapter 3, 132 HTV-2 seropositive subjects and 160 HTV- 
seronegative subjects were recruited in a rural village in Guinea-Bissau between 
January and May 1991 of which PBMC samples were available from 127 HTV-2 
seropositive subjects and 160 HTV-seronegative subjects. HTLV provirus DNA was 
detected in 31 (24.4%) of the HTV-2 seropositive PBMC samples and in 15 (9.4%) of 
the HTV seronegative samples by qualitative PCR (Chapter 3). All HTLV PCR 
positive samples were diagnosed as HTLV type I by the restriction enzyme analysis.
ii Characteristics o f subjects
The mean age, sex ratio, mean CD4% of subjects in the HTV-2-seropositive and HTV- 
seronegative subjects with or without HTLV-I infection are shown in Table 6.1. In 
HTV-2-seropositive subjects, HTLV-I infection was significantly associated with 
older age (p = 0.01, t test) and with being female (p < 0.0001, Fisher's exact test) and 
the mean CD4% was significantly higher in HTLV-I infected individuals than in 
HTLV-I uninfected individuals (p = 0.049, t-test). However these associations were 
not significant in the HIV-seronegative subjects.
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HIV-2 seropositive HIV-2 seronegative
HTLV-I
status
positive
(n=31)
Negative
(n=96)
positive 
(n=15) .
negative * 
(n=145)
Proportion 30/31 58/96 11/15 108/145
female (96.8%) (60.4%) (73.3%) (74,5%)
MeantS.E 
age (years)
56.1±2.8 48.5±1.4 54.3±4.6 49.93=1.4
mean±S.E.
CD4%^
32.9±1.7 28.6±1.1 36.5±1.6 35.5±0.7
Table 6.1.
The sex ratio, mean age and mean CD4% in subjects according to HTLV-I and 
HTV-2 infection.
 ^CD4% was available from 110 HIV-2 seropositive and 141 HIV seronegative subjects.
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ÜL HTLV-I viral load among HIV-2 positive individuals and HIV negative individuals
Figure 6.1 shows the distribution of HTLV-I provirus copies per Ipg of DNA in HTV- 
2 seropositive individuals and HTV negative individuals. The median value for the 
HTV-2-infected subjects was 3125 (Interquartile range (I.R.), 625, 3125) copies / 1 pg 
DNA which was higher than the median of the control group which was 625 (I.R., 25, 
15625) copies / 1 pg DNA but the difference was not statistically significant (p = 0.6, 
Wilcoxon test). On the assumption that the CD4^ cell fraction harboured most HTLV- 
I virus (Richardson et al., 1990), the number of provirus copies per CD4^ cell fraction 
was calculated by dividing the number of provirus copies per 1 pg PBMC DNA by 
CD4%. There were 25 HTLV-I/HrV-2 dually infected subjects and 15 HTLV-I singly 
infected subjects for whom valid CD4% data was available. The median number of 
HTLV-I provirus copies / CD4^ cell fraction in the dually infected subjects was 3289 
( I.R. 1389, 15625 ) which was not significantly different from the median of 1953 (
I R 60, 33245 ) observed in the singly infected group (p = 0.7, Wilcoxon test). The 
number of provirus copies / 1 pg PBMC DNA was not significantly related to CD4% 
in 25 dually infected subjects with a valid CD4% data (r = - 0.049, p = 0.8 
Spearman's test), nor did HTLV-I provirus level relate to age (r = -0.07, p = 0.7, 
Spearman's test).
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Figure 61.
Histogram of HTLV-I proviral load in HIV-2-infected 
and HIV-uninfected subjects
Subject
No.
Type of 
Dilution
Dilution of cells or t)NA
1/
3125
1/
15625
1/
78125
1/
390625
1/
1953125
c61 Cell NT + 2/2 + 4/4 -0/4 -0/4
DNA NT + 1/1 + 4/4 + 3/4 -0/4
cl35 Cell + 4/4 + 2/4 -1/4 NT NT
DNA + 4/4 + 4/4 + 2/4 -0/4 NT
Table 6.2 Comparison of limiting dilution analysis using two different methods of
sample dilution.  ^ ■
It shows the number of positive reactions / number of reactions tested at a dilution of 
1.5x10® cells or equivalent amont of celluar DNA; NT, not tested; the end-point is 
indicated in bold lettering; a cellular gene, p-globin gene was detected by nested PCR 
at 1/78125 dilution but not at 1/390625 dilution in both samples prepared by two 
different methods.
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Table 6.2 shows results of limiting dilution analysis of either PBMC or DNA from the 
two subjects, c61 and cl35, who had the highest level of HTLV-Î proviral load among 
HIV-2 seropositive and HTV-seronegative subjects respectively. In subject c61 who was 
a 66 years old female with a CD4% of 35, the end-point dilution was 1/390,625 when 
DNA sample was diluted whereas it was 1/78,125 when the cell sample was diluted 
before DNA extraction. Similarly in subject cl 35 who was a 65 years old male with a 
CD4% of 28, the end-point dilution was 1/78,125 when DNA was diluted, while it was 
1/15,625 when cells were diluted. The dilution experiments were repeated and a 
consistent result was obtained. Thus in both cases the end-point was about five-fold 
higher if DNA was extracted before diluting sample than after diluting sample.
IV . Conqtarison between HTLV-I viral load and HIV-2 proviral load
HTLV-I provirus level was plotted in relation to HTV-2 provirus level which was 
determined in Chapter 3, in the 31 dually infected individuals (Figuré 6.2). There was 
no positive correlation between provirus level of HTLV-I and HTV-2 before (r = - 
0.33, p = 0.073, Spearman's test) or after adjusting for CD4% (r = - 0.32 p = 0.12, 
Spearman's test).
After 4 years of follow-up, 4 among 31 (12.9%) HTV-2/HTLV-I dually infected 
subjects, 11 out of 96 (11.5%) HIV-2 singly infected subjects and none of the 15 
HTLV-I singly infected subjects had died. There were 13 deaths among the 145 
(9.3%) HTV/HTLV-I uninfected subjects. After adjusting for sex and age in the HTV- 
2 infected group, the risk of death from HTLV-I infected subjects relative to HTLV-I 
uninfected subjects was 1 32 ( 95% C I 0 31, 5 56 ) (p = 0.7). The overall risk of 
death from HTLV-I infection adjusted for age, sex and HTV status was 0.66 (95% C.I. 
0.20, 2.19 )(p=0.5).
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Figure 6.2. Relation of HTLV-I proviral load to HIV-2 proviral load.
Subject (c61) who had a very high HTLV-I viral load is indicated by a 
shaded square.
6.a.3. Discussion
In this HIV-2 seropositive population, HTLV-I infection was associated with age and 
was seen more frequently in females which is consistent with previous findings in 
West Afiica (Naucler et al., 1992; Biggar et al., 1993). This data also supports the 
previous finding that there is a higher CD4% in HTLV-I/HTV dually infected 
individuals th ^  in HTV singly infected individuals (Schechter et al., 1994).
HTLV-I proviral load in the villagers was found to vary considerably by more than 
100,000 fold. A surprisingly high level of HTLV-I provirus was seen in three subjects; 
two HTV-2-infected and one HTV-uninfected. Two of these subjects were estimated to 
have HTLV-I provirus load of 0.8 x 10^  copies and one subject had 3.9 x 10^  copies / 1 
Hg DNA (Table 6.2). Assuming that Ipg of DNA is equivalent to 1.5 x 10^  cells and that 
CD4^ cells which constitute approximately 30% of PBMCs are the only cell fraction 
harboring HTLV-I (Richardson et al., 1990), the two subjects were estimated to have 
had 1.7 X 10^  copies and the other one had 8.7 x 10^  copies per 1.0 x 10^  CD4^ cells. 
Thus there were more HTLV-I proviruses than the number of susceptible cells. When 
DNA was extracted after diluting the PBMCs in two of the subjects: c61 and cl35 
(Table 6.2), it was found that the number of infected cells was at least five-fold less than 
the number of HTLV-I provirus, suggesting that an infected cell contains on average 
five copies of HTLV-I provirus. Assuming that the number of infected cells was five­
fold less than the number of HTLV-I proviruses, subject, cl 35 seemed to have had more 
than 30% of CD4^ cells infected with the virus whereas subject c61 appeared to have 
had almost all CD4^ cells infected.
Several mechanisms by which HTLV-I could stimulate HTV replication have been
tested in vitro. The HTV-2 rev-responsive element has been reported to be responsive
to the HTLV-I rex gene product (Lewis et al., 1990; Sakai et al., 1990) and HTLV-I
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tœc and rex products interact indirectly with the LTR region by up-regulating the 
expression of some cellular factors such as IL-2 and IL-2 receptors (McGuire et al.,
1993). In addition, pseudotype virus formation which confers on HTV-l a wider cell 
tropism, is thought to be another mechanism (Lusso et al., 1990; Landau et al., 1991). 
Whatever mechanisms are involved, the expression of HTLV-I genes is crucial for the 
interaction with HTV; hence the effect of HTLV-I on HTV replication in vivo is 
thought to relate to the level of HTLV-I provirus. However in this study any positive 
relation between HTLV-I proviral load and HTV-2 proviral load was not found. 
Infection of both HTV-2 and HTLV-I within a single cell may be required to produce 
a synergistic effect and to significantly influence the basal level of transcription of 
HTV-2. It is of interest to note that one subject (c61) who had a saturated level of 
HTLV-I provirus and in whom many CD4^ cells were likely to have been doubly 
infected, did not have a high HTV-2 proviral load (Figure 6.2). Final conclusions 
should not be drawn from the HTV-2 proviral load data but will have to wait until the 
HTV-2 plasma RNA viral load data is available. However the measurement of HTV 
proviral load is probably sensitive enough to detect the effect of HTLV-I since the 
HTLV-I establishes persistent infection which is thought to influence HTV-2 
replication chronically. Thus the above evidences of viral load of HTLV-I and HTV-2 
in doubly infected individuals suggest that HTLV-I infection may not have a marked 
effect on HTV-2 replication in vivo and therefore may not affect HTV-2 mortality. So 
far four years follow-up data support this concept for the mortality rate among HTV-2- 
infected individuals with HTLV-I co-infection was not higher than that of those 
without HTLV-I co-infection. However because of the long incubation time of HTV-2 
disease, formal determination of effect by HTLV-I on HTV-2 disease progression may 
require a much longer follow-up.
HTLV-I has been known to cause various clinical manifestations such as adult T-cell
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leukemia and lymphoma, tropical spastic paraparesis/HTLV-I-associated myelopathy, 
uveitis, arthropathy, broncopeumonitis, dermatitis (reviewed by CDC, 1993). The 
pathogenesis of such diseases remains poorly understood. However if any of the 
HTLV-I associated diseases is directly affected by the burden of virus (Gessain et al, 
1991), it is important to know whether HTV infection influences HTLV-I viral load or 
not. In this study it could not be demonstrated that HTV-2 infection influenced on 
HTLV-I proviral load though the number of subjects may not have been large enough 
to demonstrate a small effect. A clinical survey of HTLV-I-associated diseases in the 
village is currently in progress to address some of these issues.
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6 .b. The impact of Plasmodium falciparum parasitaemia on HIV infection
6 .b.l. Introduction
Malaria infection can be prevented by affordable prophylactic drugs in many 
developing countries where both HTV and malaria infections are common. In West 
Africa, many HIV-infected individuals are living in a malaria hyper-endemic area. 
Therefore it is important to ascertain if infection with P. falciparum affects HFV 
disease progression and transmission. Although the effect of HTV infection on malaria 
has been studied by a number of groups (Simooya et al., 1988; Muller et al., 1990; 
Allen et al., 1991; Greenberg et al., 1991), little is known of the impact of malaria on 
HTV infection. In Chapter 3, it was shown that the geometric mean HTV-2 proviral 
load was not different between individuals with and without Pf. parasitaemia. 
However since malaria parasitaemia is thought to be transient and because most 
villagers have intermittent parasitaemia, it would be difficult to demonstrate the effect of 
malaria by cross-sectional study. Therefore in this chapter, viral load of HTV-infected 
adults living in a rural village in Guinea-Bissau were compared in the end of the dry- 
season, when there is little transmission of malaria parasites, and in the following wet 
season when malaria infection is common.
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6.b.2 Results 
L Study subjects
A total of 22 HIV-uninfected and 33 HTV-infected adults of whom 2 were HTV-l and 
31 were HTV-2 positive, living in the village, were bled in May 1996 just before the 
first rain started and in October 1996 at the peak of the rains when number of malaria 
cases is usually high.
ii Prevalence and density o f Plasmodium falciparum parasitaemia
Overall the prevalence of Pfalciparum parasitaemia increased slightly during the wet 
season from 4/55(7.3%) to 7/55 (12.7%) and the median (interquartile range) density 
of parasitaemia increased significantly from 17.5 (15 -  135) parasites per pJ of blood 
to 335 (65 -  1000) parasite per pi of blood. Four HTV-infected individuals: 1 HTV-l 
and 3 HTV-2 were found to have P.falciparum parasitaemia at the time of sampling: 
one during the dry and 3 during the wet season while 29 HTV-infected individuals had 
no detectable parasitaemia in both blood samples.
iU, HIV viral load
HTV RNA was detected in plasma samples of 25/33 (76%) adults during the dry 
season and 23/33 (70%) during the wet season. In 8 HTV-2 adults, HTV-2 RNA was 
not detected in both samples whereas in all adults HTV proviral DNA was detected in 
both samples. Geometric means (95% confidence interval) of HTV RNA viral load 
among adults in whom HTV RNA was detected in either samples and of DNA viral 
load were summarised in Table 6.3.
Overall there is no tendency of increase in either HTV RNA or DNA viral load during
the wet season as compared to during the dry season. Interestingly among adults
without P f  parasitaemia in both samples, a significant decline of RNA viral load was
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noticed during the wet season. On the contrary, there was a tendency for both RNA 
and DNA viral load to increase among adults at the time they had P.f. parasitaemia 
(Figure 6.3). This increase in RNA viral load among adults with P.f. parasitaemia was 
significant as compared with the change observed among adults without P.f. 
parasitaemia (p=0.015 by t-test). However if RNA viral load was adjusted for season, 
the difference was not significant (p=0.11). The increase in DNA viral load among 
adults with P.f. parasitaemia was not significant (p=0.1 by t-test).
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Dry season Wet season Difference*
RNA viral load in all 4074 2570 p=0.3
subjects (n=25) (1585, 10233) (1096, 6166)
RNA viral load in subjects 4786 2884 P=0.035
without P.f. parasitaemia (1660, 13804) (1096, 7762)
(n=21)
DNA viral load in all 7.2 9.1 p=0.3
. subjects (n=27) (3.2, 17.0) (3.7, 22.4)
DNA viral load in subjects 7.6 9.1 P=0.7
without P ./ parasitaemia (3.1, 19) (3.4, 24.5)
(n=21)
Table 6.3.
Geometric means (95% C.L) of RNA viral load and DNA viral load between the 
dry season and the wet season.
Geometric means of RNA copies / ml of plasma and DNA copies /10^ PBMC are 
calculated; adults without detectable RNA were excluded from calculation for 
geometric RNA viral load.
*The significance of difference was tested by paired t-test.
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iv. Changes in CD4^ cell count
CD4/CD8 subset data was available for 32 HIV-positive adults and 23 HIV-negative 
controls. Changes in CD4 and CDS count are summarised in Table 6.4. Although 
CD4% was stable between the dry season and the wet season among HIV-positive 
adults, a significant decline of absolute CD4 count was observed during the wet 
season. Among HTV-negative controls, CD4% was significantly higher during the wet 
season but the absolute CD4 count was not significantly different between the 
seasons. In both HTV-positive and negative groups, a significant decline of 
lymphocyte count was noticed. However no significant change of CD4 count was 
associated with p^asitaemia in either group.
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Group Dry season Wet season Difference
All HTV-positive CD4% 32.2 33.8 P=0.207
adults (n=32) (%) (29.0, 35.3) (31.0, 37.2)
Absolute CD4 1287 976 P=0.006
(count/|il) (1091, 1483) (808, 1144)
Lymphocyte 4088 2916 P=0.001
(count/pil) (3502, 4674) (2456, 3376)
All HTV- CD4% 38.3 44.1 P<0.001
negative (%) (35.1,41.5) (40.1,48.1)
controls (n=23) Absolute CD4 1555 1271 P=0.09
(count/|xl) (1267, 1843) (1061, 1481)
Lymphocyte 4187 3091 P=0.017
(count/^il) (3351, 5023) (2461, 3721)
Table 6.4. Mean (95% C.L) CD4 cell count in the dry season and in the wet 
season.
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6.b.3. Discussion.
In this village, a marginal increase in the prevalence of parasitaemia but a significant 
increase in the density of parasitaemia was observed during the wet season. This 
pattern of parasitaemia in adults is typical of areas with seasonal but reasonably high 
levels of malaria transmission (Molineaux et al., 1988). Therefore one can expect that 
the population of this village is exposed to several infectious mosquito bites per 
annum, and that the vast majority of these occur during the wet season. Thus this 
preliminary observation suggests that exposure to malaria during the wet season itself 
does not enhance the rate of HIV replication in malaria-immune adults but the 
presence of detectable levels of parasites in the peripheral blood may have m  
enhancing effect. Malaria has been known to be a strong stimulator of B cells 
(McGregor et al., 1970) and induction of malaria specific immune response is likely 
to involve activation of T helper cells (Ballet, et al., 1987; Troye-Blombery et al.,
1994). More recently blood stage antigens o ïP.falciparum have been shown to 
stimulate CD4^ T cells of malaria-immune adults (E Lee manuscript in preparation). 
Increased size of activated CD4^ T cells may explain the increase in HTV replication, 
since activated CD4^ T cells are susceptible to HTV productive infection (Stevenson 
et al., 1990). Alternatively malaria infection may suppress HTV-specific cell-mediated 
immunity (Whittle et al., 1984, 1990; Riley et al., 1988). Accumulating evidences 
have shown that increased viral load was associated with faster rate of disease 
progression (Mellors et a l, 1995, 1996; Henrard et al., 1995; Phillips et al., 1996; 
Ruiz et al., 1996; de Wolf et al., 1997). In this study, though, decline of CD4^ cell 
count was not observed in association with parasitaemia. This was thought because in 
adults with partial immunity to Pfalciparum, parasitaemia is transient and it is 
plausible that significant changes in CD4^ cell count would only become apparent if 
parasitaemia persisted for longer. However even a transient increase in HTV 
replication may increase the probability of HTV transmission as it has been suggested
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that a high maternal viral load is a strong risk factor of mother-to-child HTV-l 
transmission (Fang et al., 1995; Dickover 1996). In countries where expensive anti­
retroviral therapy can not be a choice of management or prevention of HTV-infection, 
alternative way of improving patient’s life is needed.
Intriguingly among adults without P ./ parasitaemia, a significant decline of RNA 
viral load was observed during the wet season. Also a significantly higher CD4% was 
observed during the wet season among HTV-negative controls and a significantly 
lower lymphocyte count was observed in both HTV-positive and negative adults. 
These changes may be a reflection of the same phenomenon such as cytokine 
environment may change seasonally.
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Chapter 7.
PGR analysis of HIV-1 and HIV-2 proviruses in dually seroreactive individuals 
7.a. Comparison between qualitative PCR and serodiagnosis
7.a.l. Introduction.
As discussed in the general introduction (Chapter 1), HIV-infected individuals dually 
seroreactive for both HTV-l and HIV-2 are common in West Africa but the significance of 
dual seroreactivity remains unclear.
Two previous studies from Abidjan in Cote d’Ivoire have shown that 41% to 62% of 
dually seroreactive patients, as defined by Westem-Blot and specific peptide-based assays, 
are positive by PCR or culture for both HTV-l and HTV-2 (George et al, 1992; Peeters et 
al, 1994). However a substantial proportion of those subjects remained unprovcn as cases 
of mixed infection. Several reasons for the discrepancies between PCR and serology in 
dually seroreactive individuals have been postulated: the sensitivity of PCR is not 
sufficiently high; the level of proviruo is too low to be detected; cross reactive antibody 
mimics dual seroreactivity; patients are infected with diverse "strains of either HTV-l or 
HTV-2 which have à greater degree of sequence homology or with recombinant viruses of 
HTV-l and HTV-2; cross-reactive immunity elicited by preceding HTV infection aborts 
subsequent infection by the other type of HTV.
The objectives of the first part of this chapter are to improve serological diagnosis of HTV-
1/-2 dual infection and to clarify the implications of dual seroreactivity. A highly sensitive
PCR assay was applied, which can detect HTV-2 provirus in over 98% of HTV-2
seropositive individuals (Berry et al. 1994; Chapter 3) and in 100 % of HTV-l seropositive
individuals in the region (Berry et al. manuscript submitted). Using this sensitive test,
antibody titres in PCR singly positive subjects were compared with that of PCR dually
positive subjects coming from the clinic or community.
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7.a.2. Results.
L Study subjects
From January 1991 to June 1995 patients attending the MRC hospital, who were 
seropositive for both HTV-l and HTV-2 were enrolled. New dually seroreactive cases were 
identified by serially testing 26 HTV-l and 53 HTV-2 seropositive CSWs. Between January 
1993 and March 1995, 29,670 women attending the eight major government antenatal 
clinics who were part of a major study on perinatal transmission, were screened by 
serology for HTV (O’Donovan et al, 1996). Women who were dually seroreactive were 
also enrolled.
During the study period 78 patients at the hospital and 16 pregnant women were diagnosed 
as dually seroreactive based on the criteria that the sample is dually seroreactive by both 
competitive ELISA assays and PeptiLAV. Eight HTV-2 positive and one HTV-l positive 
CSWs became dually seroreactive. Of the total 103 dually seroreactive subjects, PBMC 
samples were available jfrom 76 subjects of whom 57 were hospital patients, 9 
seroconverters and 10 pregnant women.
il Qualitative PCR versus competitive ELISA and PeptiLA V
Results of initial PCR screening of dually seroreactive subjects as identified by both 
competitive ELISA and PeptiLav are shown in Table 7.1. Overall 70% were found to be 
dually positive by PCR while 20% were positive for HTV-l only and 9% for HTV-2 only. 
One subject was negative by both HTV-l and HTV-2 by PCR. When PCR results of 
hospital patients, seroconverters and pregnant women were separately analysed, there was 
a difference in the pattern among PCR singly positive subjects: the proportion of HTV-l ' 
PCR singly positive subjects was higher among hospital than community based subjects 
(15/57 vs 0/10; p=0.1); the proportion of HTV-2 PCR singly positive subjects was 
significantly lower among hospital-based than community-based subjects (3/57 vs 4/10; 
p=0.008). All seroconverters were found to be dually positive by PCR.
I l l
PCR Hospital-based Seroconverters Community-
jbased
Total
HIV-1 15 (26%) 0 0 15 (20%)
HIV-2 3 (5%) 0 4(40%) 7 (9%)
Dual 38 (67%) 9 (100%) 6 (60%) 53 (70%)
Neg 1 (2%) 0 0 1 (1%)
Total 57 (100%) 9 (100%) 10 (100%) 76 (100%)
Table 7.1.
Results of nested PCR in subjects testing dually seropositive by PeptiLav and routine 
type-specific ELISA.
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ni Qualitative PCR versus HIV-1 and HIV-2 antibody titres
Anti-HTV-1 and anti-HIV-2 antibody titres could be compared in 75 dually seroreactive 
subjects tested by PCR (Figure 7.1.). The proportion of individuals with a low titre (<10) 
of antibodies was significantly different between PCR dually and singly positive subjects. 
None of 53 PCR dually positive subjects had a low titre of either anti-HIV-1 or anti-HTV-2 
antibodies whereas 6 (40%) of 15 HIV-1 PCR positive / HTV-2 PCR negative subjects had 
anti-HTV-2 antibody titre of <10 (p<0.0001, Fisher’s exact test) and 6 (86%) of 7 HTV-l 
PCR negative / HTV-2 PCR positive subjects had anti-HTV-1 antibody titre of <10 
(p<0.0001, Fisher’s exact test). One subject who was negative for both HTV-l and HTV-2 
PCR and one subject who was positive for HTV-2 PCR only had a low antibody titre of 
<10 for both HTV-l and HTV-2.
In order to detect HTV provirus at a very low frequency of infected cells, 22 PCR singly 
positive/dually seroreactive subjects were tested four times by PCR. Three of the 15 HTV-l 
PCR positive / HTV-2 PCR negative subjects were found to be positive by repeated HTV-2 
PCR tests All three subjects had anti-HTV-2 antibody titre of^lO, However no subjects ' 
with anti-HTV antibody titre <10 were positive for both HTV-l and HTV-2 after 
quadruplicate PCR experiments. Based on this observation, dual seroreactivity was re­
defined by the combination of a positive PeptiLav and a positive ELISA at a dilution of 
1:10. 63 individuals were re-diagnosed dually seroreactive by the new definition and the 
final results of PCR tests are shown in Table 7.2. 89% of these dually seroreactive subjects 
were positive by both HTV-l and HTV-2 PCR.
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PCR Results
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Figure 7.1. Anti-HIV-1 and anti-HIV-2 antibody titres of dually 
seroreactive subjects according to PCR results.
One subject positive by PCR only for HIV-2 with both anti-HIV-1 and anti-HIV-2 
antibody titres of >1000 is subject no. 802 (Table 7.3).
4
PCR Hospital-based Seroconverters Community-
based
Total
HTV-l .6(13%) 0 0 6(9.5%)
HIV-2 1*(2%) 0 0 1*(1.5%)
Dual 41** (85%) 9 (100%) 6 (100%) 56** (89%)
Neg 0 (0%) 0 0 0 (0%)
Total 48 (100%) 9 (100%) 6 (100%) 63 (100%)
Table 7.2.
Results of nested PCR in subjects testing dually seropositive by PeptiLav and type 
specific ELISA at dilution of 1:10.
* This subject (subject 802) tested positive for HTV-l PCR subsequently (Table 7.3).
** Three subjects with a very low level of HIV-2 provirus were included.
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IV. Longitudinal observation ofHIV-1 andHIV-2 provirus detection in dually infected 
individuals
To examine if HTV-2 provirus decreases to undetectable levels after dual seroconversion, 
HTV-l and HTV-2 provirus were sequentially tested in 10 subjects who were successfully 
followed for more than a year. The mean interval between tests was 21 months (range: 15 
to 28 months). PCR results, CD4%/CD8% and anti-HTV-1 and anti-HTV-2 antibody titres 
are shown in Table 7.3. In the majority of subjects, PCR results remained the same but in 
two subjects the PCR result changed during follow-up: one subject (no 802), in whom 
HTV-l provirus was not initially detected, became positive for HTV-l PCR in the second 
sample; another subject (no 674) who was initially positive by HTV-2 PCR became 
negative during the follow-up; this second sample was negative even when tested 10 times.
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Subject date HIV-1
PCR
HIV-2
PCR
CD4
%
CDS
%
Anti-HTV- 
1 Ab
anti-HTV-2
Ab
063 Sep. 91 Positive Positive 42 37 100 >1000
Dec. 93 Positive Positive 27 37
021 Jan. 92 Positive Positive 25 39 >1000 >1000
Nov. 94 Positive Positive 23 43
802 Jun. 91 Negative Positive 16 74 >1000 >1000
Sep. 92 Positive Positive 12 73
674 Jan. 92 Positive Positive 16 69 >1000 10
Apr. 93 Positive Negative 9 . 70
123 May 92 Positive Positive 20 58 >1000 100
Jan. 94 Positive Positive 20 46
080 Aug. 92 Positive Positive 8 70 100 100
Aug. 94 Positive Positive 2 31
840 Apr. 93 Positive Positive 6 83 >1000 >1000
Jun. 95 Positive Positive 4 81 •
220 May 93 Positive Positive 6 66 >1000 >1000
Dec 94 Positive Positive 3 44
940 Oct. 93 Positive Positive 16 63 100 >1000
May 95 Positive Positive 17 64
415 Oct. 93 Positive Positive 24 64 10 >1000
May 95 Positive Positive 28 57
Table 7.3.
Longitudinal observations of UlV-l and EŒV-2 provirus among 10 dually seropositive 
subjects.
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7.a.3. Discussion.
It was observed that the majority of dually seroreactive individuals were infected with both 
HTV-l and HTV-2 as judged by initial PCR screening which has been shown in previous 
studies. However even with two highly specific antibody assays: competitive ELISA and 
peptide-based assay and the use of a highly sensitive PCR revealed a proportion of dually 
seroreactive individuals who were singly positive by PCR. Two explanations for this 
discrepancy were examined in this study.
Firstly HTV proviral load was thought to be too low to be detected by a single nested PCR 
test. A nested PCR test able to detect a single molecule (Berry et al, 1994), was used to 
examine 1x10  ^cells. Thus if the frequency of cells harbouring HTV provirus is less than 
one in 1x10  ^cells, a single nested PCR test may fail to detect viral genome. In order to 
detect the virus at a very low frequency, PCR negative individuals were examined with 
four more tests and three more subjects were found to have a very low level of HTV-2 
proviral DNA. It was also observed that in one patient the level of HTV-2 provirus declined 
to undetectable levels after 15 months of follow-up, indicating that HTV-2 provirus might 
occasionally be undetectable despite a genuine mixed infection, provided that the first 
HTV-2 PCR result was not due to a laboratory contamination. A similar phenomenon has 
been observed by in vitro culture of PBMCs from dually infected individuals in which 
HTV-2 became undetectable after 6 weeks of culture while HTV-l remained detectable 
(Peeters et al, 1994). In another patient, HTV-l provirus was not detected in the first 
sample but was detected in the second sample. One possible explanation is that the first 
sample was taken close to the time of superinfection and dual seroconversion and the HTV- 
1 infection may have only been present at too low a level at the time of sampling.
Secondary antibodies against one type of HTV cross-react with heterotypic viral antigens 
and often mimic dual seroreactivity. In this study it has been shown that there is a
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significant difference in antibody titres between PCR dually positive and PCR singly 
positive individuals and that even with multiple PCR tests, viral DNA was not detected 
among those with a low titre, indicating that antibodies with a titre of <10 were mostly 
likely to be cross-reactive in origin rather than due to superinfection.
Based upon the above observation, after redefining dual seroreactivity as a positive 
PeptiLav and a positive competitive ELISA for both HIV-1 and HTV-2 at a serum dilution 
of 10, 56/63 (89%) of dually seroreactive individuals were found to be dually infected by 
PCR. All 53 PCR dually positive subjects in Table 7.1 flillfilled this new definition. 
However 6 (9.5%) subjects could not be shown to be dually infected by quadruplicate 
PCR. Since antibody profiles of these six subjects were indistinguishable from PCR dually 
positive individuals, it was believed that these individuals were genuinely dually 
seroreactive as a result of dual infection but that some harboured only an undetectable level 
ofHTV-2.
It was found that when dual seroreactivity was diagnosed using both the competitive 
ELISA and the peptide-based assay, 18/57 (32%) of hospital-based subjects were positive 
by PCR for only one HTV type which was mostly HTV-l whereas 4/10 (40%) of dually 
seroreactive community-based subjects were positive by PCR only for HTV-2 only (Table 
7.1). Thus this data shows that if the less vigorous definition of dual seroreactivity of low 
stringency is applied, the pattern of PCR results may vary considerably in different study 
populations. With a more stringent definition for dual seroreactivity which incorporated 
dilution prior to assaying, this problem was greatly reduced (Table 7.2). For the purpose of 
seroepidemiological studies, economical and practical methods for serodiagnosis of dual 
infection are needed. Although titration of HTV type-specific antibody is tedious, this study 
showed that competitive ELISA at 1/10 dilution was sufficiently accurate as was 
previously shown (Tedder et al, 1988). Various criteria for dual seroreactivity have been
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used in different studies (George et al, 1992; Peeters et al, 1994). Difference in results of 
comparison between PCR and serology may be due both to a variation of serological 
diagnostic criteria and also to a difference in study population Careful standardisation of 
any method to be used remains a necessary procedure.
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7.b. Comparison of HTV-l and HIV-2 proviral load among dually infected
individuals
7.b.l. Introduction.
Genomic structures of HTV-l and HTV-2 are very similar and there is some amino-acid 
sequence identity. Thus when an individual with one type of HTV is exposed or co-infected 
with the other type of HTV, significant immunological and virological interactions between 
the two viruses are expected. A study of a cohort of commercial sex workers (CSWs) in 
Senegal has suggested that 70-75% of HTV-2 infected individuals are protected fi-om 
subsequent HTV-l infection (Travers et al, 1995). However the finding was 
methodologically controversial as selection of HTV-uninfected control CSWs was unclear 
(Greenberg et al, 1996) and such a gross level of cross-protection has not been found in 
other cohorts (Aaby et al, 1997; Ariyoshi et al, 1997: supplement to Chapter 7). 
Nonetheless, there are several reasons to believe that a protective effect may be plausible. 
Cytotoxic T-lymphocytes (CTL) elicited by one type of HIV cross-reactively recognise the 
other type of HIV (Nixon et al, 1990; Rowland-Jones et al, 1995; Bertoletti et al, 1997). 
Neutralising antibodies have been shown to cross-react (Weiss et al, 1988; Bottiger et al, 
1990). Some C-C chemokines: MlPla, MIPip and RANTES, which can block infection of 
both HTV-l and HTV-2 have also been described (Cocchi et al., 1995).
The aim of the second part of this chapter is to study the interaction between HTV-l and 
HTV-2 in vivo by measuring HTV-l and HTV-2 proviral load among dually infected 
individuals.
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7.b.2. Results. 
i  Study subjects.
Of 56 HTV-l and HTV-2 PCR dually positive patients identified in the first part of Chapter 
7, 34 hospital patients and 8 seroconverters {7 seroconverters fi-om HTV-2 single infection 
and 1 fi-om HTV-l single infection} were tested by quantitative PCR. The first part of this 
chapter also found 7 individuals who were genuinely dually seropositive by a new 
stringent criteria: both anti-HTV-1 and anti-HTV-2 antibody titres >10 but did not have 
PCR-proven mixed infection. Of those, 5 patients: 4 HTV-l PCR positive / HTV-2 PCR 
negative and 1 HTV-l PCR negative / HTV-2 PCR positive patients who had valid CD4^ 
cell count data, were also shown in some analysis.
i t  Specificity o f HIV-type specific quantitative PCR
In order to evaluate the specificity of HTV-type specific quantitative PCR, 11 HTV-1- 
infected subjects and 11 HTV-2-infected subjects were tested with HTV-2-specific and 
HTV-l-specific quantitative PCR respectively. None of HTV-2 singly infected subjects or 
HTV-l singly infected subjects tested by heterotypic HTV-quantitative PCR showed any 
radiometric signal which was higher than the signal of the smallest copy number of 
positive standard control (3 copies /10^ PBMCs).
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Hi Comparison of HIV-1 proviral load and HIV-2 proviral load among dually infected 
individuals.
Geometric means of CD4 adjusted HTV-l and HTV-2 proviral load were calculated among 
42 patients with PCR-proven dual infection (Table 7.4). The geometric mean of HTV-l 
proviral load was significantly higher than that of HTV-2 proviral load. When patients were 
categorised into three CD4 groups, the difference was highly significant only among those 
with a low CD4% of <14% whereas the viral load was similar among patients with a 
relatively high CD4% >14%.
Five PCR singly positive patients with genuine dual seroactivity by the new stringent 
criteria, were not included to calculate the geometric means in Table 7.4. However it was 
noteworthy that the median (range) CD4% of the 5 dually seroreactive patients without 
PCR-proven mixed infection was significantly lower than the median (range) CD4% of 42 
dually seroreactive patients with PCR-proven mixed infection {3.0% (1-17%) versus 
18.5% (4-43%) respectively; p=0.017 by Wilcoxon two-sample test}.
HTV-l proviral load and HTV-2 proviral load in 42 dually infected patients were compared 
by plotting them in a scatter gram (Figure 7.2 ). The correlation between the two types of 
viral load was not significant (r = - 0.12, p>0.1 by Spearman’s test). The figure also 
showed the viral load of 5 dually seropositive patients without PCR-proven mixed 
infection, assuming that the other type of HTV was under detectable level by nested PCR 
but they were not included in the analysis for the correlation. It was noteworthy that none 
of dually infected patients had both HTV-l and HTV-2 proviral load lower than 10 
copies/1 o’ PBMCs.
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IV. Proviral load in relation to CD4  ^cell count
CD4 adjusted HTV-l proviral load was plotted in relation to their CD4% (Figure 7.3). A 
significant inverse correlation was noticed (r= - 0.47 p=0.002, Spearman’s test). On the 
other hand when CD4 adjusted HIV-2 proviral load was plotted in relation to CD4%, no 
significant inverse correlation was found (r= - 0.11, p=0) (Figure 7.4 ).
The figures also show the viral load of 5 dually seropositive patients without PCR-proven 
mixed infection but the analysis for the correlation did not include the five PCR singly 
positive patients.
V. HtV-proviral load in subjects who became duaUy infected during follow-up.
The mean of CD4^ cell count and the geometric means of HTV-l and HTV-2 DNA viral 
load among known converters were compared with the other patients (Table 7.5). The 
mean CD4% among converters from HTV-2 single infection to dual infection was 
significantly higher than that among the other hospital patients (p=0.01). The geometric 
mean HTV-2 DNA viral load was similar between converters and the other hospital 
patients. The geometric mean of HTV-l DNA viral load among converters from HTV-2 
single infection was lower than that among the other hospital patients but after adjusting 
for CD4%, there was no difference between the two groups (p=0.5). The five dually 
seropositive patients without PCR-proven mixed infection were not included in this 
analysis.
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CD4
(%)
*HIV-1 proviral 
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load
Seroconverters
.
HTV-1 to dual 38 486 36
(n=l)
-
HIV-2 to dual 27.4 191 112
(n=7) (19.9, 35.0) (16, 2334) (27, 469)
Dually infected 179 1483 239
hospital patients 
(n=34)
(14.2,21.6) (533, 3966) (100, 573)
Table 7.5.
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7.b.3. Discussion.
One of the main objectives of the second part of HTV-l/HrV-2 dual infection study is to 
see if pre-existing HIV-2 protective immunity is sufficiently cross-reactive to suppress the 
growth of the superinfecting HTV-l and to prevent from HTV-disease progression. It was 
shown that when macaques pre-infected with HTV-2 were challenged with diverse strains 
of pathogenic STVsm, although they were not protected from STV infection, they were 
protected from STV-disease progression by reducing STV viral load (Putkonen et al. 1995). 
Therefore cross-reactive protective immunity elicited by preceding HTV-2 infection may 
not confer compete protection against HTV-l infection. However like in the HTV-2/STV 
model, the cross-reactive protective immunity may suppress an initial surge of super- 
infecting m V -l during the HTV-l primary infection more efficiently than HTV-uninfected 
individuals, and as a consequence dually infected individuals have a lower level of HTV-l 
provirus than HTV-l singly infected individuals. In order to test this hypothesis, HTV-l 
proviral load among dually infected patients was compared with previous data of HTV-l 
proviral load among TUV-l singly infected patients (Berry et al. manuscript submitted) 
(Table 7.4). The comparison was made possible since the HTV-l quantitative PCR assay 
used for the previous study was essentially same as for this chapter and the study subjects 
for the both studies were recruited from the same cohort in The Gambia. There was not any 
significant difference in the geometric means of HTV-l proviral load between dually 
infected patients and HTV-l singly infected patients in any of CD4 groups (p>0.1). 
Therefore this observation does not support the initial hypothesis. Several reasons were 
thought for this lack of evidence of cross-protection. Firstly the proportion of HTV-2 
infected individuals who have cross-protection may be so small that the difference was not 
demonstrated by the simple overall eomparison of proviral load. It is noteworthy that there 
were four subjects whose HTV-l proviral load was relatively low of <10 copies / 10^  CD4^ 
despite an abnormally low CD4% <29%. The presence of cross-protection may be 
restricted by limited alleles of class 1 and/or class n  MHC molecules. HLA typing of whole
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dually infected individuals is warranted. Secondly in 34 dually infected subjects it was not 
known if they were converted to dual infection from HTV-l or HTV-2 single infection. 
HTV-l proviral load may not be low if dually infected individuals were converted from 
HTV-l single infection. However as it was discussed in Chapter 1, epidemiological data 
indicate that HTV-l epidemic started later than HTV-2, suggesting the majority of dually 
infected individuals were converted from HTV-2 single infection. In addition, the mean 
HTV-l proviral load of the eight converters from HTV-2 single infection was not 
significantly different from that of the other dually infected patients (Table 7.5). Thirdly 
the replication of both viruses may be mutually enhanced thus the partial cross-protective 
effect may have been cancelled out. Antagonistic CTL by cross-reactive CTL was also 
thought as a mechanism for the mutual enhancement (Klenerman et al., 1994; Meier et al.,
1995). This possibility has recently been tested by Rowland-Jones et al., and B27-restricted 
cross-reactive CTL was not found to induce antagonism (Rowland-Jones et al., manuscript 
submitted). Virologically Tat and Rev of one type of HTV can act upon the other type of 
provirus, though HTV-2 Tat and HTV-2 Rev act on HTV-l TAR and RRE less efficiently 
than HTV-l Tat and HTV-l Rev act on HTV-2 TAR and RRE (Chapter 1). Although a 
positive correlation was not found between HTV-l and HTV-2 proviral load among dually 
infected patients, without RNA viral load data one can not conclude that there is no mutual 
stimulation of HTV replication. Further investigation of HTV-l and HTV-2 RNA viral load 
in dually infected individuals is necessary.
The other main finding in the second part of this chapter is that dually infected individuals 
with a low CD4% had a significantly lower HTV-2 proviral load than HTV-l proviral load. 
When TTTV-2 proviral load was also compared with HTV-2 proviral load data among HTV-2 
singly infected individuals in the previous study (Berry et al., manuscript submitted) (Table 
7.4), it was found that the level of HTV-2 provirus in dually infected individuals was 
significantly lower than that in HTV-2 singly infected individuals among the groups with a
131
CD4%<14% and 14-28% (p=0.033 and p=0.01 respectively). Intriguingly the four dually 
seroreactive patients with negative PCR results for HIV-2 provirus also had a low CD4% 
(Figure 7.4). Therefore it is plausible that these four patients had a very low level of HTV-2 
provirus which was not detectable. Mechanisms for the lower HTV-2 proviral load among 
dually infected individuals in advanced disease have been thought. First, the EBV-specific 
CTL precursor frequencies are known to be maintained in advanced HTV-l infection while 
HTV-l-specific CTL activity selectively deteriorates (Carmichael et al. 1993). Thus in this 
group of patients, HTV-2-specific CTL may maintain. Second, since HTV-l and HTV-2 use 
common co-receptors such as CCR3, CCR5 and CXCR4, in addition to CD4 molecule 
(Bron et al 1997), the target cell population is likely to be shared by the two viruses. As 
HTV-l Nef and Vpu are known to down-regulate surface expression of CD4 molecules 
(Garcia et al., 1991; Aiken et al., 1994; Kerkau et al., 1997), cells infected with HTV-l may 
become resistant to the superinfection (Benson et al., 1993). Thus competition of infecting 
a limited number of target cells may become apparent among those with a few number of 
CD4^ cells and fast-growing HTV-l may dominate the target cells. Third, 
immunosuppression in the dually infected individuals is mainly caused by HTV-l with 
rapid/high replication capacity while slow/low replication capacity of HTV-2 may remain.
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Chapter 8  
General discussion 
S.a. The role of HIV-2 viral load in the pathogenesis of HIV-2 infection.
From the extensive studies of HTV-l viral load, it is now widely believed that viral load is 
important in the pathogenesis of AIDS as the turnover rate of HTV-l productively infected 
cells is directly related to the rate of CD4^ T-cell loss. Thus patients with a high rate of 
HTV-l replication in vivo, which is more closely reflected by the high level of HTV-l RNA 
in plasma than proviral DNA in lymphocytes, have a rapid turn-over of HTV-l- 
productively infected cells which results in a decline in CD4^ T-cell count. This thesis has 
shown that the burden of HTV-2 virus is also an important determinant for the pathogenesis 
of HTV-2-induced ATDS for the level of HTV-2 RNA in plasma, in particular, correlates 
with a rate of CD4‘" T cell decline and with death. Therefore like HTV-l infection, the rate 
of CD4^ T-cell loss is likely to be directly related to the rate of turn-over of HTV-2 
productively infected cells.
8 .h. Why do HlV-2-infcctcd individuals live for long?
One of the main aims in this thesis has been to measure HTV-2 viral load in order to answer 
the central question why HTV-2-infected individuals live longer than HTV-l-infected 
individuals. However findings in Chapter 3 raised a paradox as the level of HTV-2 proviral 
DNA in healthy individuals living in a rural village in Guinea-Bissau was high and more or 
less equivalent to that of the provirus in asymptomatic HTV-l subjects as reported in 
published papers. However in that study, HTV-2 proviral load was not compared with the 
level of HTV-l proviral DNA in African population living in the same environment. Berry 
et al, have recently compared the proviral load of HTV-l and HTV-2 patients attending the 
MRC hospital and again found that there was no significant difference in proviral DNA 
load after adjusting for their CD4^ cell count (Berry ct al.,.manuscript submitted). Thus the 
conclusion is that HTV-2-infected individuals live longer not because they have
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successfully eradicated the virus but because they are able to live with a substantial amount 
of HTV-2 provirus. The same study showed that the most obvious difference between the 
two infections was that RNA viral load of HTV-2 patients with a high CD4^ cell count was 
much lower than that of similar HTV-l infected patients (Berry et al., manuscript 
submitted). Interestingly the difference in the mortality between HTV-l and HTV 2 infected 
patients attending the hospital was significant only in the group of patients who had a 
normal CD4^ cell count at entry to the study but not in the other groups of patients (S 
Jaffar, personal communication). Thus HTV-2-infected individuals in the early phase of 
disease have a disproportionally high level of proviral DNA in relation to of RNA as 
compared with HTV-l-infected individuals. Although a proper comparison between HTV-l 
and HTV-2 viral load should be made using community-based patients before reaching a 
final conclusion, the low level of HTV-2 RNA, but not HTV-2 DNA, is likely to be the main 
mechanism for the better prognosis of HTV-2 infection.
8.C. Why is the level of HIV-2 RNA virus in plasma low?
The next question is why the level o f  HTV-2 RNA virus in plasma is low despite a 
substantial level of HTV-2 DNA. Using the model postulated in Chapter 1, two possibilities 
may explain the lower level of HTV-2 RNA in plasma. One is that if the production of 
HTV-2 virions per cell is as high as in HTV-l infection and if the half life of productively 
infected cell is similarly short, the size of productively infected cell pool must be small 
(Figure 8.1). The other explanation is that if the production of HTV-2 virions per cell is low 
and the half life of productively infected cell is long, the size of the productively infected 
cell pool may be large (Figure 8.2). In both cases the number of cells dying would be small 
and the level of RNA in plasma low. A study which measures the frequency of HTV-2- 
infected cells expressing mRNA may give more insight into the mechanisms of the low 
level of HTV-2 RNA in plasma. Other crucial questions which need answering in order to 
understand HTV-2 virus population dynamics are the proportion of HTV-2 proviruses which
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are replication-competent, which types of cells, harbour HIV-2 proviruses, and the half life 
of HTV-2-productively infected cells. HIV-2 population dynamics may differ significantly 
from HIV-1 population dynamics.
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8 .d. What factor determines the low HIV-2 RNA viral load?
During acute infection, HIV-1-infected individuals have a high level of viraemia before the 
seroconversion and in the majority of patients the level of virus in plasma declines sharply, 
coinciding with the development of HTV-specific host-immune responses such as CTL but 
not with neutralising antibodies (Ariyoshi et al., 1992; Koup et al., 1994; Borrow et al., 
1994; Connick et al., 1996). Then the viral load appears to become stabilised at a certain 
set point (Mellors et al., 1995). Therefore viral load after the acute infection is a reflection 
of the balance between the ability of the host-immune response to control viral replication 
and the replicative capability of the virus under the immune pressure. Although in HIV-2 
infection, acute HIV-2 viraemia has not been described, it is plausible that a similar 
phenomenon occurs during the acute phase of HTV-2 infection and that the level of HTV-2 
RNA is likely to be determined by the balance between the host’s immunity and the 
replicative capability of the virus.
z. Host-factors determining the low level o f HIV-2 viral replication.
The human host may develop a better immune response against HTV-2 than HIV-1. The 
role of host factors is supported by the findings in Chapter 5 that a strong HFV-2-specific 
CTL activity in asymptomatic HIV-2 patients has been found and there is an inverse 
correlation between HIV-2 proviral load and CTL activity. HIV-2-specific CTL activities 
have also been demonstrated in fresh PBMC (Gotch et al., 1993) and frequently cross- 
recognise HIV-1 antigen (Rowland-Jones et al., 1995; Bertoletti et al., 1998). In addition, 
neutralising antibodies (NA) against autologous viruses have been readily demonstrated in 
HTV-2-infected individuals (Bjorling et al., 1993). One explanation for the efficient 
immune response to HIV-2 is that HIV-2 antigen may be presented more efficiently or 
more conserved regions may be presented by HIV-2 as compared with HIV-1. The recent 
finding that the Vpu protein down-regulates the surface expression of MHC class I 
molecule, is interesting as the protein does not exist in HIV-2 (Kerkau et al., 1997). HIV-1
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Nef has also been suggested to be important as a mechanism for evading the immune 
system as it down-regulates the expression of the MHC class I molecule (Schwartz et al.,
1996) and up-regulate Fas-Ligand (Xu et al., 1997). It is, therefore, important to find if 
HIV-2 Nef has a similar function or not.
Alternatively the viruses intrinsically replicate at a low level with the result that escape 
mutants emerge infrequently and CTL and NA are effective.
a. Viral factors determining the low rate o f HIV-2 replication.
The lower rate of viral replication may be a results of intrinsic factor in the virus. If the 
host immunity is the major factor determining the low IHV-2 viral load, IHV-2 isolates 
from an infected individual should grow to a high titre in in vitro when co-cultured with 
donor cells from HIV-naive individuals where host-immune suppression no longer takes 
place. Limited information suggests that this is not the case for even after several passages 
the virus remains at low titre, suggesting intrinsic factors are also important in regulating 
viral replication (Evans et al., 1988; Kong et al., 1988; Albert et al., 1990). However it 
remains unknown if the dominant population of slow/low viruses which are usually found 
in mV-2-infected asymptomatic individuals, is due to a selective advantage of such 
viruses. Within IHV-2 viruses, the slow/low viruses may be recognised by the immune 
system less efficiently than the rapid/high viruses as the slow/low viruses present less viral 
antigen than the rapid/high viruses. Therefore it is difficult to discuss host and viral factors 
separately.
The interaction between host cellular factors and enhancers in the LTR region is an 
important factor which determines the rate of HIV replication. As discussed in Chapter 1, 
there are substantial differences in the structure of enhancers of the HTV-l and IHV-2 LTR 
regions and thus cellular factors, such as TNF, activate HIV-2 LTR differently from HIV-1 
LTR. Therefore HIV-2 may be less efficiently enhanced by various co-infection than HIV-
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1; this may be one reason why HTV-2 RNA viral load is low. In this thesis, the interactions 
of HIV-2 with HTLV-I and malaria were investigated. Although there was no evidence 
that co-infection with HTLV-I enhanced HIV-2 proviral load, a small increase in HTV-2 
viral load was noticed among individuals with malaria parasitaemia (Chapter 6); the trend 
may be more obvious in HTV-l infection, however in this study only one HTV-l infection 
with malaria parasitaemia was observed. It would be interesting to do a similar study in 
HTV-l infection. More studies to compare the enhancing effects of various co-infections on 
HTV-l and HTV-2 replication are needed.
The other important factor determining the rate of HTV-2 replication is the characteristics 
of the susceptible host cell population. The observation that HTV-2 primary isolates use a 
wider range of chemokine receptors is intriguing since it suggests that the susceptible cell 
population may be different between HTV-l and HTV-2 (Bron et al., 1997; Heredia et al., 
1997; McKnight et al., manuscript submitted). Currently HTV-2 envelope glycoprotein has 
been found to bind to CD8 as well as to CD4 molecules on human T cells (Kaneko et al.,
1997). If cell population susceptible to HTV-2 is less activated than that of HTV-l, this 
would explain the smaller size of productively infected cell population. The study ofHTV- 
2 infected cell population in vivo is warranted.
Although the reasons for the lower transmission rates of HTV-2 are not addressed in this 
thesis, it is plausible that the lower HTV-2 viral load may relate to the low rate of 
transmission since in HTV-l infection maternal RNA viral load appears to be associated 
with vertical transmission (Fang et al., 1995; Dickover et al., 1996). The data presented in 
this thesis supports the hypothesis that the lower infectivity of HTV-2 may be due to the 
lower rate of HTV-2 virus replication resulting in a lower viral load.
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8.e. Other possible explanation for the better prognosis of HIV-2 infection
The African Green monkey is the natural host for SIYagm- The virus does not cause 
immunodeficiency in this host although SIYagm replicates at a substantial rate (Hartung et 
al. 1991). It remains unknown if some strains of HIV-2 replicate to a high titre without 
killing infected cells as does SlVagm in its natural host. The turnover of the HTV-2- 
productively infected cells as compared with the turn-over rate of HTV-l-productively 
infected cells has not been investigated. This question can be answered by comparing HTV- 
1 and HTV-2 viral kinetics in patients receiving potent anti-retroviral drugs. An alternative 
approach is to conduct a survival analysis of HTV-l or HTV-2-infected patients who are 
matched for base-line CD4^ cell count and base-line RNA viral load.
8.f. Summary
The host-virus relations in HTV-l and HTV-2 infections are compared and summarised in 
Table 8.1. The conclusion is that in general HTV-2-infected individuals live longer than 
HTV-l infected individuals not because they have eradicated the virus but because they are 
able to tolerate a substantial level of HIV-2 provirus wliich does not replicate as fast as 
HTV-l. This low steady-state in HTV-2 infection is established either because the HTV-2 
virus intrinsically grows at low rate or because the human host can develop efficient 
immune response which controls HTV-2 viral replication or both. Possible research areas 
are summarised in Table 8.2. The main reason for this low steady-state relationship 
remains largely unknown.
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HTV-l infection HTV-2 infection
RNA viral load -H-+ » +
DNA viral load ++ = ++ .
Biological properties rapid/high > slow/low slow/low > rapid/high
Intra-patient variability High > low?
Efficient CTL ++ < -HH+?
Autologous NA Low < high?
Escape mutant (CTL) Frequent > less frequent?
Escape mutant (NA) Frequent > less frequent?
Table 8.1. Summary of host-virus relations in HTV-l and HTV-2 infections.
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Research fields Hypothesis
Host factors
Neutralising antibody epitopes and its NA epitopes in HTV-2 are more
escape mutant conserved
CTL epitopes and its escape mutants CTL epitopes in HTV-2 are more
conserved
Viral factors
HTV-2 virus kinetics A half life of HTV-2 productively infected 
cells is long.
LTR functions of HTV-2 slow/low viruses HTV-2 LTRs are less responsive to 
various cellular factors
Co-receptor usage of HTV-2 slow/low HTV-2 uses different co-receptors and
viruses and cell population infected with 
HTV-2 provirus
infects different cell populations
Nef function of HTV-2 slow/low viruses HTV-2 Nef does not down-regulates 
surface CD4 and MHC class I molecule
expression and does not up-regulates Fas 
ligand.
Table 8.2. Summary of important research areas of host and viral factors in HIV-2 
infection.
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Does HIV-2 infection provide cross-protection against HIV-1 infection?
A study o f  pros t i tutes  in Senegal  suggests that  H IV  2 
i n f ec t i on '  c on fe r s  7 5 %  p r o t e c t i o n  agains t  su b s e q u e n t  
HIV-1 infection |1| .  T h e r e  are several reasons to believe 
that such a protect ive effect may  be plausible,  as cross­
r ea c t i v e  c y t o t o x i c  T - l y m p h o c y t e s  ( C T L )  b e t w e e n  
H IV -1  and  H I V - 2  | 2 , 3 | ,  c ro s s - r e ac t i v e  neu t r a l i z i n g  
ant ibodies  | 4 ,5 | ,  and  C - C  c h e m o k i n e s  that  can block 
i n f ec t i on  o f  b o t h  H I V - 1  an d  H I V - 2  | 6 |  h ave  been  
descr ibed.
T h e  Ciambia is o n e  of the  ve ry  few coun t r i es  w he re  
H I V - 2  has been  p re sen t  s ince befor e  t he  HIV-1  ep i ­
demic  started [7| .  T o  con f i rm  the  hypothes is  that  H I V -  
2 p r o t e c t s  a g a i n s t  H I V - 1  i n f e c t i o n  w e  h a v e  
r e t r o sp ec t i ve ly  ana lysed  H I V - 1  i n c i d e n c e  data  f r om 
504  ini t ial ly s e r on ega t i ve  and  87  H I V-2 - se ro pos i t i ve  
commerc i a l  sex work e r s  ( C S W ) . i n  T h e  Gambia ,  w h o  
w e re  seen at t he  Med i ca l  R es e a r c h  C o u n c i l  ( M K C )  
cl inic b e t w e e n  J u n e  1988  an d  Ju l y  1995.  Sera w e r e  
tested twice  o r  m or e  in 189 se ronega t i ve  and 53 H I V -  
2-seroposi t ive  subjects by  a H I V  type-speci f ic  c om p e t i ­
t i ve  e n z y m e - l i n k e d  i m m u n o s o r b e n t  assay ( M u r e x  
Diagnost ics,  Dar t ford,  Ken t ,  U K)  and a pept i de-based 
im nu in o en z ym a t i c  strip m e t h o d  (Pep t iLAV;  Diagnost ic  
Pasteur ,  M a r n e s - l a - C o q u c t t e ,  France) .  Dua l  i nfect ion 
was  c o n f i r m e d  by  ne s t ed  p o ly m er a s e  cha i n  r eac t i on  
w i th  H I V  type - spec i f i c  l o n g  t e r m i na l  r epea t  ( L T R )  
pr imers  (kindly p rov id ed  by  D r  N .  Berry,  Univers i t y  
Co l l ege  L o nd o n ,  L o n do n ,  UK) .  M e a n  age,  the  p r o p o r ­
t ion o f  C S W  w i t h  ac t ive syphilis at  r e c r u i tme n t ,  and 
t he  i n c i d en ce  o f  c u l t u r e - p r o v e n  g o n o r r h o e a  d id  no t  
s ignif icant ly differ  b e t w e e n  the  t w o  g r oup s  (Tab le  1;
P >  0.1); h o w e v e r ,  the  i nc idence  rate o f  HIV-1  infec­
t ion a m o n g  H IV -2 -p o s i t i v e  C S W  was 8.7 pe r  100 pe r ­
son-years  o f  observa t ion  (PYO), be in g  h igh e r  t han  that  
o f  H I V - n e g a t i v e  C S W  (5.4 pe r  100 PYO). T h e  rate 
ratio o f  1.7 (95% con f id enc e  interval ,  0 . 7 -3 .9 )  suggests 
a sl ight ly i nc r ea sed  risk fo r  H I V - 2 - i n f e c t e d  w o m e n .  
T h e  o b s e r v e d  H I V - 1  i n c i d e n c e s  in o u r  c o h o r t  a rc  
st r ikingly h ig he r  than those in the  Senegalese s tudy (1.1
pe r  100 P Y O  in H IV - 2 - i n f ee t e d  w o m e n  and  2.5 per  
100 P Y O  in H IV -n eg a t i v e  w o m e n )  (1]. A l though  o u r  
data did  n o t  a l l ow ad ju s t me n t  for  unsafe sexual  prac­
tices,  it does  n o t  sup p o r t  t he  hypothes is  that  ther e  is 
substantial  p ro t ec t i on  against  H lV -1  infect ion by p r e ­
ced ing  H l V - 2  infect ion.
T h e  appa ren t  d i f ference b e tw e e n  the T raver s  study | 1|  
and  o u r  s t udy  suggests that  it may  be difficult to consis­
t en t l y  d e m o n s t r a t e  e v i d e n c e  o f  c r o s s - p r o t e c t i o n  by 
H I V - 2  against  H l V - 1 .  Epidemiolog ica l  factors such as 
t h e  l eve l  o f  e x p o s u r e  t o  H I V - 1  m a y  h a v e  v a r i e d  
b e t w e e n  t he  t w o  studies.  B iological  factors ma y  also 
vaiy,  and  expe r i men t s  w i th  m o n ke y s  suggest  that  there 
is a w i n d o w  pe r iod  b e t w ee n  i nfect ion w i th  a t tenuat ed  
v i ruses  a n d  s u b s e q u e n t  p r o t e c t i o n  aga ins t  cha l l eng e  
w i t h  p a t h o g e n i c  s imian  i m m u n o d e f i c i e n c y  virus  f8| .  
T hu s ,  the du ra t i on  o f  p r eced ing  H l V - 2  infect ion may 
i n f l u e n c e  t h e  i n t e r a c t i o n  o f  H I V - 1 a n d  H I V - 2  
i n f ec t i ons .  I f  p r o t e c t i o n  d id  exis t  and  was  m ed i a t e d  
ma in ly  by  C T L ,  on ly  s o m e  H l V - 2 - i n f e c t e d  subjects  
w i th  c e r t a in  h u m a n  l e u k o c y t e  an t i gen  (H LA)  alleles 
s u c h  as H L A - B 2 7  a n d  H L A - B 3 5 ,  w h i c h  c r o s s -  
react ively recogni ze  HIV-1  [2,3| ,  may  be  p ro t ec t ed  by 
p r e c e d i n g  H l V - 2  i n f ec t i on .  Suscep t i b i l i t y  o f  H IV -1  
may also, var)'  a cc o rd ing  to t he  g en o ty pe  o f  the infect­
i ng H lV -1  virus,  and finally, an u nd e t e r m i n e d  p r o p o r ­
t ion o f  H I V - n e g a t i v e  C S W  in H I V - 2  e n d e m i c  areas 
may  be  resistant to H I V  infec t i on ,  as has be en  observed 
in Na i rob i  | 9 | .  In conclus ion ,  w e  emphas i ze  that  fur­
t h e r  ep id e m io l o g i c a l ,  v i r o log i ca l  a nd  i m m u n o l o g i c a l  
studies are r equ i r ed  to e lucidate  h o w  the  tw o  types o f  
H I V  interact .
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Table 1. C haracteristics of initially HIV-2-positive and  HIV-negative com m ercial sex w orkers.
IR (9.S% Cl)
G roup
M ean (SD) 
years of age
Proportion with 
active syphilis at 
enro lm ent (95%  Cl) PYO
No. HIV- 1 
infections HIV-1 G onorrhoea
HIV-2-positive 
HIV negative 
Rate ratio
53
189
29.2 (5.4)
28.2 (5.2)
0 .33  (0 .20-0 .46) 
0 .24  (0 .18-0 .30)
92 .0
369.2
8
19
8.7 (4 .3 -17 .4) 
5.1 (3 .3-H .I) 
1.7 (0 .7 -3 .9 )
8.9 (4 .9 -17 .8 ) 
9.5 (b.8 -13 .2 ) 
0 .9  (0 .4 -2 .0 )
Incidence rales (IR) per 100 person-years of observation  (PYO) of gonorrhoea  an d  HIV-1, and  the resulting rate ratios are show n; active 
syphilis w as d iagnosed  if both Tre/yoncme pallidum  haem aggliitin  assay and  rapid plasm a reagin tests w ere |X)sitive. Cl, C onfidence interval.
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